Investigating a Novel Receptor that Mediates Vasoconstriction in Mouse Femoral Arteries

Joselia Carlos, The University of Western Ontario

Supervisor: McGuire, John, The University of Western Ontario

A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in Medical Biophysics

© Joselia Carlos 2021

Follow this and additional works at: https://ir.lib.uwo.ca/etd

Part of the Medical Biophysics Commons, and the Pharmacology Commons

Recommended Citation

https://ir.lib.uwo.ca/etd/8289

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.
Abstract

The synthetic peptide trans-cinnamoyl-leucine-isoleucine-glycine-arginine-leucine-ornithine-amide (tcLIGRLO) causes smooth muscle contraction in mouse femoral arteries. The identity of the receptor that mediates this response is undetermined. We hypothesize that the novel mechanism for tcLIGRLO-induced contractions involves a G-protein coupled receptor (GPCR) and a Gq-Ca2+ signalling pathway. Chapter 2 describes experiments using femoral arteries isolated from male and female systemic protease-activated receptor 2 (PAR2KO) mice (n=31; 21 – 39 weeks of age) using tcLIGRLO and the Gq-inhibitor, YM-254890 (YM). Contractions produced by tcLIGRLO did not differ by sex but decreased as age increased. YM inhibited tcLIGRLO-induced contractions. Chapter 3 describes preliminary work to identify a human GPCR for tcLIGRLO, other than PAR2, using the TANGO assay to screen four candidates. We identified a potential human GPCR target that warrants additional study. In conclusion, tcLIGRLO activates a novel mechanism involving a Gq-coupled receptor. This novel mechanism may have potential significance in vascular biology.

Keywords

tcLIGRLO, G-protein coupled receptor, Gq, calcium signalling, smooth muscle contraction, YM-254890, orphan receptor, protease-activated receptor 2, TANGO assay
Summary for Lay Audience

We have a test compound called tcLIGRLO that causes smooth muscle contraction in a mouse artery. We do not know how the compound works but we believe it is a novel receptor for which no drugs have yet been designed to target. We used a compound called YM to block the pathways for a common type of receptor called G-protein coupled receptors or GPCRs. We found YM blocked our test compound. We also screened some candidate human GPCRs as targets of tcLIGRLO. We found some evidence that one of these receptors was activated by tcLIGRLO. In summary, we discovered more details about a novel mechanism found in mouse blood vessels and a potential human receptor that could have relevance to human vascular pathophysiology.
Co-authorship statement

Joselia Carlos conducted all experiments, data collection, and analyses unless otherwise noted below.

Dr. John McGuire conceived the research projects outlined in this thesis, advised, and supervised JC on experimental design, conducting experiments, analyses and interpretations of data, the presentation of results and the writing, editing, revising of drafts of this entire thesis.

Chapter 1.2 is a piece of writing by JC from early drafts of a systematic review on YM submitted for scientific publication and currently, is in revision.

The authorship details of this manuscript are: Joselia Carlos, Haleh Zabihi, Andrea N. Wang, and John J. McGuire. Discovering G protein coupled receptor signals: a review of the Go_{q/11} inhibitor YM-254890. 51 pages. 160 references.

Experiments with ecPAR2KO mice (Chapter 2.3.2) were conducted in concert with Haleh Zabihi, but only the work completed by JC is reported.

Dr. Rithwik Ramachandran was instrumental in the design, execution, analyses, and interpretation of Ca^{2+} signalling studies (Chapter 2) and the TANGO assay (Chapter 3).

Under Dr. Ramachandran's supervision Victor Mirka (grad student) provided technical assistance to JC for conducting experiments, and preliminary data analyses in Chapters 2.3.4 and 3.3.1.
Acknowledgments

This research was a Discovery Grant awarded to Dr. McGuire (principal investigator) by the Natural Sciences and Engineering Research Council (NSERC). Joselia Carlos received a Western Graduate Research Scholarship.

This thesis would not have been possible without the contribution and support of several people. Firstly, I would like to thank my supervisor, Dr. John McGuire, for your continuous guidance. Thank you for introducing me to the field of cardiovascular pharmacology. Your ambitiousness and perseverance are truly admirable.

Thank you to my committee members—Dr. Jefferson Frisbee, Dr. Krishna Singh, and Dr. Rithwik Ramachandran. Thank you all for your input and guidance. Thank you, Jeff, for your “life advice” from our occasional chats. I enjoyed our brief chats because I always gained some novel insight on not just in science, but also in life. Thank you, Krishna, for your expertise on molecular biology techniques. Your work ethic and humility are commendable. Thank you, Rithwik, for basically welcoming me as an additional member in your laboratory during this masters. Your expertise on cell work and patience are highly appreciated. I really did enjoy getting to know the members of your lab.

I would like to thank my fellow lab members—Cheng Lim, Qing Zong, Ryan Singer, Haleh Zabihi, Caroline Marszal, and Andrea Wang—for creating a positive lab environment. Thank you, Cheng and Qing, for teaching me wire myography. Thank you, Ryan, Haleh, and Andrea, for your assistance in data collection. As well, thank you Haleh for co-writing the YM review article with me. Most importantly, thank you, Andrea, for being my confidant during my graduate studies. As the only two graduate students in the lab, we faced a lot of obstacles together—one of them being completing two-thirds of our masters in the middle of a global pandemic. I am thankful for our friendship.

Thank you, Victor Mirka, for helping me to troubleshoot and optimize my TANGO experiments in addition to your own thesis work. While the TANGO experiments took a lot longer than expected, I will always appreciate your unwavering support.
Thank you, David Michels and Dr Lyn Wang, for helping out with genotyping. Thank you, Mariola, for managing our mice and promptly having the mice ready for us every morning on the day of experiments.

Thank you to my parents for supporting me emotionally and financially as I embarked on this thesis. Lastly, thank you, Cullen, for your emotional support and for being my encourager throughout this whole process.
# Table of Contents

Abstract................................................................................................................................. ii
Summary for Lay Audience ........................................................................................................ iii
Co-authorship statement ........................................................................................................... iv
Acknowledgments .................................................................................................................... v
Table of Contents ..................................................................................................................... vii
Abbreviation and Glossary .......................................................................................................... xi
List of Tables ............................................................................................................................ xiii
List of Figures .......................................................................................................................... xiv

## Chapter 1

1 Introduction............................................................................................................................. 1

1.1 tcLIGRLO: a PAR2-activating peptide ................................................................................. 3

1.2 YM: a tool for investigating GPCR signals .......................................................................... 8

1.2.1 Introduction to YM .......................................................................................................... 8

1.2.2 GPCRs and heteromeric G proteins ............................................................................... 8

1.2.3 Investigating PAR2 with YM ......................................................................................... 9

1.2.4 Uses of YM to study vascular smooth muscle contraction ........................................... 10

1.2.5 Refining characteristics of GPCRs and discovering novel Gq-mediated signalling mechanisms ......................................................................................................................... 14

1.3 Orphan receptors: a class of GPCRs whose ligands remain unknown ............................. 14

1.3.1 Introduction to orphan receptors ..................................................................................... 14

1.3.2 Techniques for de-orphanization ...................................................................................... 15

1.3.2.1 Reverse pharmacology .............................................................................................. 15

1.3.2.2 TANGO and PRESTO-TANGO assay ..................................................................... 16

1.3.3 Lesser known and uncharacterized receptors: SUCNR1, CCRL2, GPR15, and GPR135 ......................................................................................................................... 19
1.3.3.1 SUCNR1: a de-orphanized receptor ................................................. 19

1.3.3.2 The remaining orphans: CCRL2, GPR15, and GPR135 ................. 20

1.4 Thesis statement, hypothesis, objectives, rationale ......................................... 23

Chapter 2 ................................................................................................................. 25

2 Role of G_q in tcLIGRLO-induced contractions of mouse vascular smooth muscle .... 25

2.1 Introduction ............................................................................................................. 25

2.2 Materials and methods .......................................................................................... 25

2.2.1 Chemical reagents and drug solutions ............................................................. 25

2.2.2 Animals ............................................................................................................. 26

2.2.2.1 Ethics Statement on the care and use of animals in research .... 26

2.2.2.2 Mice ............................................................................................................. 26

2.2.3 Wire Myograph Experiments ........................................................................... 27

2.2.3.1 Isolation of femoral arteries ................................................................. 27

2.2.3.2 DMT myographs ....................................................................................... 27

2.2.3.3 Normalization of baseline tension for femoral arteries ................. 27

2.2.3.4 Vascular smooth muscle contraction and relaxation bioassay protocols .......................................................................................... 28

Substudy 1: Sex and age in PAR2KO mice ....................................................... 28

Substudy 2: Effects of YM on femoral arteries from PAR2KOs ................... 29

Substudy 2.1. tcLIGRLO and YM ................................................................. 29

Substudy 2.2. Phenylephrine and YM ............................................................... 29

Substudy 2.3. KCl and YM .................................................................................. 29

Substudy 3: ecPAR2KO ...................................................................................... 29

Substudy 3.1. tcLIGRLO dose-response curves .............................................. 29
Substudy 3.2. Ach and SNP relaxation ................................................................. 29

2.2.4 Cell lines ........................................................................................................ 30
2.2.5 Ca²⁺ signalling ............................................................................................ 30
2.2.6 Data analysis and statistics ........................................................................... 31

2.3 Results .............................................................................................................. 34
2.3.1 Effects of sex and age on tcLIGRLO-induced contractions ....................... 34
2.3.2 Effects of the G₉ inhibitor YM on femoral arteries .................................. 42
2.3.2 tcLIGRLO effects in ecPAR2KO mice ........................................................ 47
2.3.3 Effects of the G₉ inhibitor YM on Ca²⁺ signals in PAR2WT HEK293 cells ...................................................................................................................... 51

2.4 Discussion ...................................................................................................... 55
2.4.1 Age-related effects on tcLIGRLO-mediated contractions ......................... 55
2.4.2 tcLIGRLO-mediated contractions are G₉-dependent .................................. 57
2.4.3 YM inhibition of PAR2 Ca²⁺ signalling pathway ....................................... 57

Chapter 3 ............................................................................................................ 59
3 Assessing for GPCR activation with the TANGO assay .................................... 59

3.1 Introduction ..................................................................................................... 59
3.2 Materials and Methods .................................................................................. 60
3.2.1 Chemical reagents and drug solutions ....................................................... 60
3.2.2 Cloning and transfection .......................................................................... 61
3.2.3 Luciferase reporter assay ............................................................................ 61
3.2.4 Data and statistical analyses ..................................................................... 62

3.3 Results ............................................................................................................ 63
3.3.1 PAR2 activation with tcLIGRLO, SLIGRL, 2fLIGRLO ............................. 63
3.3.2 Effects of tcLIGRLO on CCR2L2, GPR15, GPR135, and SUCNR1 expressing HTLA cells in TANGO assay ................................................................. 66
# Abbreviation and Glossary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ach</td>
<td>Acetylcholine</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>cAMP</td>
<td>Cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>Ca²⁺</td>
<td>Calcium ion</td>
</tr>
<tr>
<td>CCRL2</td>
<td>C-C chemokine receptor-like 2, a type of GPCR</td>
</tr>
<tr>
<td>CRC</td>
<td>Concentration response curve; in this thesis, is used synonymously with dose-response curve</td>
</tr>
<tr>
<td>DAG</td>
<td>Diacylglycerol</td>
</tr>
<tr>
<td>ecPAR2KO</td>
<td>Endothelial cell-specific protease-activated receptor 2 knockout</td>
</tr>
<tr>
<td>EC₅₀</td>
<td>Molar concentration of drug or activator producing 50% of Eₘₐₓ</td>
</tr>
<tr>
<td>Eₘₐₓ</td>
<td>Maximum effect produced by an activator or agonist</td>
</tr>
<tr>
<td>eNOS</td>
<td>Endothelial nitric oxide synthase; encoded by nos3</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular signal-regulated kinase</td>
</tr>
<tr>
<td>GDP</td>
<td>Guanine diphosphate</td>
</tr>
<tr>
<td>GPCR</td>
<td>G-protein coupled receptor; in this thesis, is specific to the 7 transmembrane receptor form</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanine triphosphate</td>
</tr>
<tr>
<td>HBSS</td>
<td>Hank’s Balanced Salt Solution</td>
</tr>
<tr>
<td>HEK293</td>
<td>Human embryonic kidney 293 cells</td>
</tr>
<tr>
<td>HTLA</td>
<td>HEK293 cells stably expressing a tetracycline transactivator-dependent luciferase, reporter, and a β-arrestin-2-Tobacco Etch Virus fusion gene</td>
</tr>
<tr>
<td>IC₁</td>
<td>Internal circumference of blood vessel at resting tension and is equal to 90% of IC₁₀₀ (see abbreviation below)</td>
</tr>
<tr>
<td>IC₅₀</td>
<td>Concentration of inhibitor that produces 50% of Eₘₐₓ</td>
</tr>
<tr>
<td>IC₁₀₀</td>
<td>100% internal circumference of blood vessel under pre-determined target transmural pressure 13.3kPa (100mmHg)</td>
</tr>
</tbody>
</table>
IP$_3$  Inositol triphosphate
KO  Knockout; referring to targeted gene deletion
PAR  Protease-activated receptor
PAR1  Protease-activated receptor 1
PAR2  Protease-activated receptor 2; encoded by par2 ($F2lrl$) gene
PAR2AP  PAR2-activating peptide, all peptide sequences are amides unless otherwise noted
PBS  Phosphate buffer saline
PKC  Protein kinase C
PIP$_2$  Phosphatidylinositol 4,5-bisphosphate
PRESTO  Parallel receptor-ome expression and screening via transcriptional output
RhoA  Ras homolog family member A
ROCK  Rho-associated protein kinase
SNP  Sodium nitroprusside
SLIGRL  serine-leucine-isoleucine-glycine-arginine-leucine
S.E.  Standard error of the mean
SUCNR1  Succinate receptor 1, a family of GPCRs
TANGO  transcriptional activation following arrestin translocation
tcLIGRLO  trans-cinnamoyl-leucine-isoleucine-glycine-arginine-leucine-ornithine
WT  Wildtype, also refers to the control strain
2fLIGRLO  2-furoyl-leucine-isoleucine-glycine-arginine-leucine-ornithine
YM  YM-254890; (R)-1-((3S,6S,9S,12S,18R,21S,22R)-21-acetamido-18-benzyl-3-((R)-1-methoxyethyl)-4,9,10,12,16,22-hexamethyl-15-methylene-2,5,8,11,14,17,20-heptaoxo-1,19-dioxoa-4,7,10,13,16-pentaazacyclodocosan-6-yl)-2-methylpropyl (2S,3R)-2-acetamido-3-hydroxy-4-methylpentanoate
List of Tables

Table 1. Comparison of pEC<sub>50</sub> values for PAR2-mediated signalling with PAR2-activating peptides tcLIGRLO, SLIGRL, and 2-fLIGRLO in intracellular Ca<sup>2+</sup> signalling and blood vessel relaxation assays ................................................................. 6

Table 2. List of agents, their respective targets, and effects on 50µM tcLIGRLO-mediated contractions .................................................................................................................. 7

Table 3. Summary of pIC<sub>50</sub> values for YM inhibition of G protein couple receptors and ligands signalling in vascular smooth muscle contraction ................................................. 12

Table 4. Summary table providing tissue distribution profile, G-protein signalling, putative ligands, and reported physiological roles of CCRL2, GPR15, SUCNR1, and GPR135 .......... 21

Table 5. A summary table of physical characteristics of mice (weight and age) and femoral arteries (length and diameter) and sample size ........................................................................ 32

Table 6. A summary table of pEC<sub>50</sub>, E<sub>max</sub>, and sample size values of tcLIGRLO and phenylephrine drug treatments in PAR2KO mice ................................................................................. 39

Table 7. E<sub>max</sub> values of tcLIGRLO-mediated contractions of male PAR2KO femoral arteries from three different age groups ......................................................................................... 41

Table 8. E<sub>max</sub> and pEC<sub>50</sub> values of tcLIGRLO- and phenylephrine-induced contractions following YM treatments in femoral arteries from male PAR2KO mice .............................................. 45

Table 9. pEC<sub>50</sub> and E<sub>max</sub> values of Ach- and SNP-induced relaxation in femoral arteries from ecPAR2KO and WT mice following pre-contraction to 3µM phenylephrine .................................. 50

Table 10. E<sub>max</sub> and pEC<sub>50</sub> values of PAR2 activation with PAR2-APs in PAR2-transfected HTLA cells in the TANGO assay .................................................................................................. 65
List of Figures

Figure 1. Schematic of tcLIGRLO mechanisms of action in mouse blood vessels. ..................2

Figure 2. Schematic representation of the TANGO assay. ....................................................18

Figure 3. tcLIGRLO-induced contractions of femoral arteries from male PAR2KO mice....35

Figure 4. tcLIGRLO-response curves in male vs female PAR2KO femoral arteries. ..........36

Figure 5. Phenylephrine CRCs in male vs female PAR2KO femoral arteries.....................37

Figure 6. Ach and SNP relaxation response curves in femoral arteries from male PAR2KO mice. ..................................................................................................................................................38

Figure 7. Effect of age on tcLIGRLO contractions of male PAR2KO femoral arteries.......40

Figure 8. YM inhibition of tcLIGRLO-mediated contractions in femoral arteries of PAR2KO male mice..................................................................................................................................................43

Figure 9. YM inhibition of phenylephrine-mediated contractions in femoral arteries of PAR2KO male mice..................................................................................................................................................44

Figure 10. K\(^+\) contractions in the presence and absence of YM.................................46

Figure 11. tcLIGRLO-mediated contractions in ecPAR2KO and PAR2WT femoral arteries. ....................................................................................................................................................48

Figure 12. Ach- and SNP CRCs in ecPAR2KO and PAR2WT femoral arteries............49

Figure 13. tcLIGRLO-mediated Ca\(^{2+}\) signalling in PAR2KO and PAR2WT HEK293 cells. 52

Figure 14. YM inhibition of PAR2-activated Ca\(^{2+}\) signalling for tcLIGRLO-treated PAR2WT HEK293 cells................................................................................................................................................53

Figure 15. tcLIGRLO-mediated Ca\(^{2+}\) signalling in PAR2WT HEK293 cells..............54
Figure 16. PAR2 activation with SLIGRL, 2fLIGRLO, and tcLIGRLO in PAR2-transfected HTLA cells using the TANGO assay........................................................................................................64

Figure 17. TANGO luminescence of tcLIGRLO treated HTLA cells-expressing PAR2, SUCNR1, GPR135, GPR15, or CCRL2. ........................................................................................................................................67
Chapter 1

1 Introduction

The seven transmembrane domain G-protein coupled receptors (GPCRs) are highly druggable targets, with over 700 approved drugs targeting this protein superfamily (Sriram & Insel, 2018). Over 800 genes encode GPCRs, whose known ligands consist of hormones, neurotransmitters, chemokines, ions, odourants, and physical stimuli (Pierce et al., 2002). There are also about 100 GPCRs, which are referred here as orphan GPCRs, having no ligands identified yet. Protease-activated receptor 2 belongs to the protease-activated receptors (PARs) family whose endogenous activators are serine proteases (Barrios et al., 2003; Coughlin et al., 1992; Feld et al., 2013; Vergnolle et al., 1998a). PAR2 is expressed in many tissues, but its particular expression on the endothelium, and its many effects on endothelium functions highlight the interest in its role in cardiovascular health and disease (Kagota et al., 2016; J. McGuire, 2004; Vergnolle et al., 2001) The PAR2-activating peptide (PAR2AP) trans-cinnamoyl-LIGRLO-NH₂ (tcLIGRLO) is one of several synthetic ligands, which were developed to mimic the tethered ligand mechanism of activation of PAR2 by proteases. Nevertheless, tcLIGRLO exhibits biological activities that cannot be explained by PAR2 activation (McGuire et al., 2002; Stenton et al., 2002; Vergnolle et al., 1998a). In particular, McGuire et al. (2002) discovered tcLIGRLO produced smooth muscle contraction in mouse femoral arteries (Figure 1). The two overlapping goals of this thesis is to further delineate the mechanism of contractions \textit{ex vivo} and identify a human GPCR target of tcLIGRLO, other than PAR2. We anticipate the outcomes of this thesis will lead to further exploration of a novel mechanism, potentially involved with vascular heath and receptors in human diseases.
PAR2 activates $G_q$, $G_{12/13}$ and $G_i$ signals in endothelial cells. PAR2-$G_{12/13}$ and PAR2-$G_i$ signalling are associated with downstream signalling pathways that involve cytokine release and RhoA and ERK activation (Avet et al., 2020; Suzuki et al., 2009). tcLIGRLO activates PAR2 which results in processes associated with pathophysiological functions of the endothelium. tcLIGRLO also activates an unidentified receptor that directly causes smooth muscle contraction via a mechanism of contraction dependent on intracellular Ca$^{2+}$ stores. Our working hypothesis for this research is the receptor is a $G_q$-coupled GPCR. Figure created by JC using BioRender.

Abbreviations: eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; GDP, guanosine diphosphate; GTP, guanosine triphosphate; Ca$^{2+}$, calcium; DAG, diacylglycerol; IP$_3$, inositol triphosphate; PKC, protein kinase C; PLC, phospholipase C; PAR2; protease-activated receptor 2; PIP$_2$, phosphatidylinositol 4,5-bisphosphate; RhoA, Ras homolog family member A; tcLIGRLO, trans-cinnamoyl-LIGRLO
1.1 tcLIGRLO: a PAR2-activating peptide

tcLIGRLO is a second generation PAR2AP. During physiological PAR2 signalling, endogenous proteases such as the serine protease prototype, trypsin, cleave the N-terminus of PAR2 to reveal a tethered ligand sequence that binds to extracellular loop 2 of the receptor (Hollenberg et al., 2014; McGuire, 2004). High concentration of thrombin (100 – 500nM) can also activate PAR2 (Mihara et al., 2016; Ramachandran et al., 2012). tcLIGRLO activates PAR2 by mimicking the tethered ligand sequence that interacts with extracellular loop 2. Seeing how extracellular loop 2 is an important point of contact, altering the amino acid sequence of extracellular loop 2 affects the binding specificity of PAR2 agonists (Al-Ani et al., 1999). For instance, changing phenylalanine to serine at residue 40 of extracellular loop 2 induced calcium (Ca$^{2+}$) signals that were 4 times higher than the wildtype (WT) receptor (Compton et al., 2000). It was speculated that the single point mutation allowed the trans-cinnamoyl group of tcLIGRLO to dock more efficiently due to the removal of the aromatic chain (Compton et al., 2000). In addition to the interaction with PAR2, the trans-cinnamoyl group addition to a PAR1AP was reported to produce an antagonist response (Bernatowicz et al., 1996), which suggests this particular functional group as a site for interaction with GPCRs.

tcLIGRLO is equipotent to the PAR2AP SLIGRL (serine-leucine-isoleucine-glycine-arginine-leucine) for Ca$^{2+}$ signalling in PAR2-transfected cell lines and rat aortic relaxation. 2-furoyl-leucine-isoleucine-glycine-arginine-leucine-ornithine (2fLIGRLO) is the most potent out of these three PAR2APs (Table 1). Amongst these PAR2APs, the rank order potencies for Ca$^{2+}$ signals correlate with endothelium-dependent blood vessel relaxations. However, the relative potencies of tcLIGRLO and SLIGRL for inducing rat jejunal chloride transport differed greatly (Vergnolle et al., 1998b). The difference in rank order potencies for tcLIGRLO and SLIGRL in the intestinal assay compared with the Ca$^{2+}$ signalling and blood vessel relaxation assays suggested potential for an unidentified receptor distinct from PAR2 in the rat jejunum that regulates intestinal transport via a prostanoid-sensitive mechanism (Vergnolle et al., 1998b). Likewise, a
subsequent study showed PAR2 mRNA expression in rat peritoneal mast cells, but tcLIGRLO stimulated the secretion of β-hexosaminidase via a PAR2-independent pathway (Stenton et al., 2002). tcLIGRLO activation of PAR2 leads to the release of cytokines and expression levels of cell-adhesion molecules on neutrophil cell surfaces (Han et al., 2003; Niu et al., 2008; Shpacovitch et al., 2004, 2007; Wang & He, 2006). Indomethacin reduced tcLIGRLO-induced edema in rat paws (Vergnolle et al., 1999), demonstrating the involvement of prostanoid-sensitive mechanisms in PAR2-mediated edema.

Similar to studies using rat aortas, tcLIGRLO and SLIGRL caused comparable relaxation to each other in mouse femoral arteries from C57BL/6J (WT) mice (Table 1). In the same study, McGuire et al. (2002) also found that tcLIGRLO caused contraction in femoral arteries by a non-PAR2 mechanism (Figure 1). The threshold tcLIGRLO concentration was 10 µM, which is ~10-times higher than its EC$_{50}$ for relaxation and 3 times higher than the maximal effective dose for relaxation. Thus, in the presence of PAR2, tcLIGRLO produces biphasic relaxation-contraction responses in normal mouse blood vessels. More interestingly, tcLIGRLO contracted endothelium-denuded arteries from WT mice, whereas SLIGRL did not. Further study of this response found that tcLIGRLO caused contraction of endothelium-intact femoral arteries from endothelial nitric oxide synthase (eNOS) gene knockout and par2 gene knockout (PAR2KO) mice. Pre-treatment of mouse femoral arteries with pharmacological compounds to inhibit known GPCRs (Table 3) did not inhibit tcLIGRLO responses in the mouse PAR2KO blood vessels. However, the selective depletion of intracellular Ca$^{2+}$ stores (Table 3) resulted in complete inhibition of the contractions by tcLIGRLO. The study concluded that tcLIGRLO contraction was a novel mechanism and warranted further work to identify the receptor. We are not aware of any further characterization of the novel mechanism of tcLIGRLO in mouse femoral arteries in scientific literature.

Figure 1 provides a summary of the mechanism of action of tcLIGRLO in mouse blood vessels and the background rationale for this thesis research. As shown in Figure 1,
tcLIGRLO is not only an endothelial cell PAR2 agonist, but also activates another receptor aside from PAR2 that mediates release of Ca\(^{2+}\) from intracellular stores in the smooth muscle of mouse femoral arteries. Our working hypothesis for this research is the receptor is a G\(_q\)-coupled GPCR (Figure 1). We will test this hypothesis using a G\(_q\) selective pharmacological inhibitor which is described in Section 2. We will also look at GPCRs whose ligands have not been well defined as potential GPCR candidates of tcLIGRLO. This class of GPCRs is referred to as orphan GPCRs and described in Section 3.
Table 1. Comparison of pEC$_{50}$ values for PAR2-mediated signalling with PAR2-activating peptides tcLIGRLO, SLIGRL, and 2-fLIGRLO in intracellular Ca$^{2+}$ signalling and blood vessel relaxation assays.

<table>
<thead>
<tr>
<th>Study</th>
<th>PAR2AP</th>
<th>Ca$^{2+}$ pEC$_{50}$</th>
<th>Blood vessel relaxation pEC$_{50}$</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>tcLIGRLO</td>
<td>5.09$^a$</td>
<td></td>
<td>(Saifeddine et al., 1998)</td>
</tr>
<tr>
<td></td>
<td>SLIGRL</td>
<td>5.09$^a$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>tcLIGRLO</td>
<td>6.10$^a$</td>
<td></td>
<td>(Vergnolle et al., 1998b)</td>
</tr>
<tr>
<td></td>
<td>tcLIGRLO</td>
<td>6.00$^b$</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SLIGRL</td>
<td>6.10$^a$</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SLIGRL</td>
<td>6.00$^b$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>tcLIGRLO</td>
<td>5.80$^c$</td>
<td></td>
<td>(McGuire et al., 2002)</td>
</tr>
<tr>
<td></td>
<td>SLIGRL</td>
<td>5.80$^c$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>SLIGRL</td>
<td>4.60 – 5.50$^a$</td>
<td>5.60 – 5.70$^{b,c}$</td>
<td>(McGuire et al., 2004)</td>
</tr>
<tr>
<td></td>
<td>2fLIGRLO</td>
<td>5.50 – 7.00$^a$</td>
<td>6.50 – 7.70$^{b,c}$</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>tcLIGRLO</td>
<td>6.00$^b$</td>
<td></td>
<td>(Hollenberg et al., 2008)</td>
</tr>
<tr>
<td></td>
<td>SLIGRL</td>
<td>5.74$^b$</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2fLIGRLO</td>
<td>6.47$^b$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a, human PAR2 transfected into rat kidney cells; b, endothelium-intact aortas from male Sprague Dawley rats; c, endothelium-intact C57BL/6J mouse femoral arteries
<table>
<thead>
<tr>
<th>Target</th>
<th>Agent</th>
<th>Inhibition of contractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin II receptor type 1</td>
<td>Losartan</td>
<td>No effect</td>
</tr>
<tr>
<td>(\alpha_1)-adrenoreceptor</td>
<td>prazosin</td>
<td>No effect</td>
</tr>
<tr>
<td>Cyclooxygenase 1/2</td>
<td>Indomethacin</td>
<td>No effect</td>
</tr>
<tr>
<td>Calcium-sensitive internal stores</td>
<td>Cyclopiazonic acid</td>
<td>Reduced contractions</td>
</tr>
<tr>
<td></td>
<td>Caffeine</td>
<td></td>
</tr>
<tr>
<td>endothelin- receptor 1A</td>
<td>BQ123</td>
<td>No effect</td>
</tr>
<tr>
<td>Histamine receptor 1/2</td>
<td>chlorpheniramine</td>
<td>No effect</td>
</tr>
<tr>
<td>Muscarinic receptors</td>
<td>Atropine</td>
<td>No effect</td>
</tr>
<tr>
<td>Neurokinin 1 receptor</td>
<td>SR140333</td>
<td>No effect</td>
</tr>
<tr>
<td>Neurokinin 2 receptor</td>
<td>SR48986</td>
<td>No effect</td>
</tr>
<tr>
<td>(\text{CdCl}_2)</td>
<td>Non-specific cation channels</td>
<td>No effect</td>
</tr>
<tr>
<td>Protease-activated receptor 4</td>
<td>AYPGKF-NH(_2)</td>
<td>No effect</td>
</tr>
<tr>
<td>Thromboxane A2 receptor</td>
<td>SQ29548</td>
<td>No effect</td>
</tr>
<tr>
<td>Voltage-gated calcium channels</td>
<td>Nifedipine</td>
<td>No effect</td>
</tr>
</tbody>
</table>

Results of compounds tested are from (McGuire et al., 2002).
1.2 YM: a tool for investigating GPCR signals

1.2.1 Introduction to YM

YM-254890 (YM) is a cyclodepsipeptide and a selective inhibitor of $G_q$ signalling by seven transmembrane GPCRs (Hermes et al., 2021; Kaur et al., 2015). YM is used to dissect, characterize, and discover novel GPCR signalling, pharmacology, and pathophysiology. Researchers recognize this utility of YM for studies developing novel drugs targeting known and lesser characterized GPCRs, and novel therapeutics targeting human disease, including chronic pulmonary disease, cardiovascular disease, and certain types of cancer (Kamato et al., 2015, 2017; Kaur et al., 2015; Touge et al., 2007; Zhang et al., 2020). Given that 35% of human GPCRs are targets of prescribed drugs, tools to allow researchers to selectively target $G_q$ signalling and apply them in appropriate in vivo models of human disease are essential (Sriram & Insel, 2018).

1.2.2 GPCRs and heteromeric G proteins

The combination of GPCR subtype and ligand determines the selectivity for the profile of G protein signalling. Generally, activated GPCRs catalyze the exchange of guanine triphosphate (GTP) with guanine diphosphate (GDP) bound to the $G\alpha$ subunit of the heterotrimeric G proteins, which leads to $G\alpha$ dissociation from $G\beta\gamma$ and activation of downstream second messenger pathways (Campbell & Smrcka, 2018). Second messenger pathways are selective for the isoforms of the $G\alpha$ subtypes (e.g. $G_s$, $G_{i/o}$, $G_q$, and $G_{12/13}$ (Campbell & Smrcka, 2018; Mizuno & Itoh, 2009) and $G\beta\gamma$-complexes. The specific effectors are also dependent on the cell type and can vary with disease and environmental cues. Targeting the inhibition of the heterotrimeric G proteins is an ongoing approach to developing therapeutics, particularly in cases where mutations produce constitutive activity (Campbell & Smrcka, 2018; Kostenis et al., 2020; Li et al., 2020), but there are obvious caveats to this approach given the ubiquitous expression of heteromeric G proteins.
Downstream of the ligand binding that stabilize the molecular conformations of activated GPCRs, YM targets the $G_q$ subtypes $\alpha_q$, $\alpha_{11}$, $\alpha_{14}$, and $\alpha_{15/16}$ (in mice and humans, respectively), which normally stimulate phospholipase C (PLC)$\beta$ (Campbell & Smrcka, 2018; Kamato et al., 2017). PLC$\beta$ hydrolyses membrane-bound phosphatidylinositol-4,5-bisphosphate (PIP$_2$) to produce diacylglycerol (DAG) and inositol trisphosphate (IP$_3$) which activate the classical ($\alpha$, $\beta$, and $\gamma$) and novel isoforms ($\delta$, $\varepsilon$, $\theta$, and $\eta$) of protein kinase C (PKC) (Bhavanasi et al., 2011; Bynagari et al., 2009; Nagy et al., 2009; Uchiyama et al., 2009), and IP$_3$ receptors, respectively. Thus, pharmacological inhibition of GPCR-mediated intracellular Ca$^{2+}$ release from intracellular stores (i.e. via IP$_3$ receptors) is a characteristic of selective inhibitors of $G_q$ and therefore, YM and YM analogues (Campbell & Smrcka, 2018; Kamato et al., 2017).

1.2.3 Investigating PAR2 with YM

YM has been used to examine differences between PAR1 and PAR2, prior to the availability of effective antagonists for PAR1 and PAR2. In endothelial cells, the regulation of eNOS activity by PAR2, but not by PAR1, was sensitive to inhibition by YM, which highlighted separate roles played by the PARs in vascular biology (Suzuki et al., 2009). The most common pharmacological tools for PAR2 are trypsin, which is used as a protease activator, and selective PAR2APs (examples mentioned in Table 1 in Section 1.1.1). Differences have been noted in the PAR2 signalling when using these PAR2 agonists. Again, YM has been used to look at these differences between PAR2 activators. YM inhibited $\beta$-arrestin recruitment following PAR2APs but not trypsin. This evidence suggests that the tethered ligand mechanism of PAR2, as demonstrated with trypsin, stimulates $\beta$-arrestin signalling independent of $G_q$ (Thibeault & Ramachandran, 2020). K-14585 is a synthetic peptide that is described as a partial PAR2 agonist. YM inhibits both IP$_3$ accumulation and p38 mitogen-activated protein kinase stimulated by 30$\mu$M K-14585 (Goh et al., 2009). As shown in Figure 1, PAR2 is reported to also activate $G_{12/13}$ and $G_i$ (Avet et al., 2020). Common to GPCRs, there is crosstalk in signalling. For instance, PAR2 activation of both $G_q$ and $G_i$ signalling includes
downstream extracellular signal-regulate kinase (ERK) activation (Avet et al., 2020; Suzuki et al., 2009). However, YM failed to inhibit Ras homolog family member A (RhoA) activation following trypsin- and PAR2AP SLIGRL, and yet, YM inhibited these same responses in cells lacking G12/13 (Avet et al., 2020). These results indicate that Gq is sufficient for activating RhoA, but this signalling mechanism is minimized in the presence of G12/13. The studies mentioned here are part of a growing body of evidence supporting the development of PAR2 ligands with selective biased signalling.

1.2.4 Uses of YM to study vascular smooth muscle contraction

YM inhibits vasoconstrictions, and vascular smooth muscle contractions by multiple GPCR ligands in different vascular preparations across species. In these cases, YM is administered prior to the GPCR ligands. Uemura et al. (2006) reported that YM caused direct relaxation of vascular smooth muscle in rat aortic rings, which had been pretreated with either thrombin, phenylephrine, serotonin, or endothelin-1, with or without an intact endothelium (pIC₅₀ 7.0 – 9.0; Table 3). In addition to its inhibition of GPCR ligands, YM is reported to inhibit the intrinsic properties of vascular smooth muscle that results in an increased myogenic tone in response to increased active stretching (Björling et al., 2018). This so-called myogenic tone is a key function that helps maintains constant perfusion over the normal physiological range of blood pressures to critically important organs such as the brain, heart, and kidneys. With preparations of larger arteries (e.g., rat aorta and rabbit basilar arteries), YM inhibited the myogenic tone induced by GPCR agonists (i.e. phenylephrine, thrombin, and endothelin-1) (pIC₅₀ 7.0 – 9.0; Table 3) (Kikkawa et al., 2010b; Meleka et al., 2019). Likewise, YM reduced spontaneous myogenic tone development in small resistance arteries i.e., mouse mesenteric arteries (Björling et al., 2018). These results provide evidence of distinct Gq signalling in mechanotransduction and initiation of contraction by endogenous ligands. Specific GPCRs such as angiotensin II type 1 receptor and cysteinyl leukotriene receptor 1 have been proposed as mechanosensors that transmit biophysical stimuli, such as stretch of smooth muscle and shear stress on endothelial cells (Schnitzler et al., 2016; Storch et al., 2015). YM inhibition of shear stress-induced endothelial cell signalling has not yet been reported.
The effects of YM on vascular smooth muscle contraction were linked partly via G\text{q} to inhibition of L-type Ca\textsuperscript{2+} channels (Meleka et al., 2019). Suppression of L-type Ca\textsuperscript{2+} channel activity in cardiomyocytes leads to decreased heart rate, contractility, and cardiac output \textit{in vivo} (Xu & Brink, 2016). As reported by Kawasaki et al. (2003), in preclinical studies evaluating the use of YM for platelet aggregation and anti-thrombosis, the putative therapeutic doses fall within the range of those reported to cause hypotension. Accordingly, their suggestion is that YM be used as local agent rather than a systemic agent (Kawasaki et al., 2003). However, based on the evidence reviewed by us, there is lack of evidence to support the use of YM as either a local or systemic agent on the circulation and platelets given the many GPCR expressed on the endothelium, and its role in both vascular tone and hemostasis.
Table 3. Summary of pIC$_{50}$ values for YM inhibition of G protein coupled receptors and ligands signalling in vascular smooth muscle contraction.

<table>
<thead>
<tr>
<th>Study</th>
<th>Receptor</th>
<th>Ligand</th>
<th>Assay</th>
<th>pIC$_{50}$</th>
<th>Model</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Endothelin receptor type A</td>
<td>Endothelin-1</td>
<td>Isometric contraction</td>
<td>7.16</td>
<td>Rabbit basilar artery with subarachnoid hemorrhage</td>
<td>(Kikkawa et al., 2010a)</td>
</tr>
<tr>
<td></td>
<td>Protease-activated receptor 1</td>
<td>thrombin</td>
<td>Isometric contraction</td>
<td>7.16</td>
<td>Rabbit basilar artery with subarachnoid hemorrhage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$\alpha_1$-adrenoceptor</td>
<td>phenylephrine</td>
<td>Isometric contraction</td>
<td>7.07</td>
<td>Rabbit basilar artery with subarachnoid hemorrhage</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Endothelin receptor type A</td>
<td>Endothelin-1</td>
<td>Isometric contraction</td>
<td>7.74</td>
<td>Rat aorta</td>
<td>(Uemura, Takamatsu, et al., 2006a)</td>
</tr>
<tr>
<td></td>
<td>$\alpha_1$-adrenoceptor</td>
<td>phenylephrine</td>
<td>Isometric contraction</td>
<td>8.80</td>
<td>Rat aorta with intact endothelium</td>
<td></td>
</tr>
<tr>
<td>Receptor Type</td>
<td>Stimulant</td>
<td>Type of Contraction</td>
<td>IC₅₀ Value</td>
<td>Tissue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------</td>
<td>---------------------</td>
<td>------------</td>
<td>----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_1)-adrenoceptor</td>
<td>phenylephrine</td>
<td>Isometric contraction</td>
<td>8.96</td>
<td>Rat aorta with denuded endothelium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-HT (^a) receptor (not specified)</td>
<td>serotonin</td>
<td>Isometric contraction</td>
<td>8.07</td>
<td>Rat aorta</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The tabulated data are derived from all studies where pIC₅₀ values were determined.

\(^a\) 5-hydroxytryptamine (i.e., serotonin)
1.2.5 Refining characteristics of GPCRs and discovering novel G\textsubscript{q}-mediated signalling mechanisms

The refinement of well characterized GPCR signalling is not the sole use for YM. The signal transduction profiles of lesser known G\textsubscript{q}-coupled receptors have been expanded using this tool. For example, YM inhibited MAS1 receptor-induced upregulation of angiotensin II type 1 receptor (Canals et al., 2006). The use of YM revealed a novel G\textsubscript{q}-mediated pathway mechanism of action for 02F04, a steroid alkaloid derivative, which leads to activation of Rho-associated protein kinase (ROCK) and ERK during the production of thymic stromal lymphopoietin in mouse keratinocytes (Mizuno et al., 2017; Weng et al., 2019). Thymic stromal lymphopoietin production is associated with severe allergy pathologies. Similarly, the identification of the GPCR mediating cholecystokinin secretion in enteroendocrine cells remains undetermined, but its inhibition by YM links it to a G\textsubscript{q}-coupled signalling mechanism (Hira et al., 2009). Of course, studies have also used the resistance to inhibition by YM to exclude G\textsubscript{q} as a requisite for cellular events. For example, YM failed to inhibit activation of apelin receptor ligand apelin-13 signalling involving ERK and early growth response factor-1 expression (Liu et al., 2015). Treatment of cells with YM had no effect on primary neurite outgrowth that was stimulated by palmitoyl-lysophosphatidylethanolamine, but did inhibit the simulation by stearoyl-lysophosphatidylethanolamine (Hisano et al., 2021). In primary cultured rat cortical astrocytes, lysophosphatidic acid stimulates the G\textsubscript{q}-coupled receptors lysophosphatidic acid receptor 1 and lysophosphatidic acid receptor 3 to induce thrombospondin-1 production, which may contribute to normal brain function, and in other cases, neurological disorders (Hisaoka-Nakashima et al., 2020).

1.3 Orphan receptors: a class of GPCRs whose ligands remain unknown

1.3.1 Introduction to orphan receptors

Within the GPCR superfamily, there is a class of receptors whose endogenous and synthetic ligands are undetermined yet; these GPCRs are formally recognized as “orphan
receptors” (Pierce et al., 2002; Sriram & Insel, 2018). Ligand binding is not always a requisite to initiate GPCR signalling e.g., in cases where receptors remain constitutively active (Kjelsberg et al., 1992; Samama et al., 1993) or dimerize prior to activation (Nelson et al., 2002). For these cases, identifying synthetic ligands is useful for revealing the signalling profile of GPCRs whose method of activation typically occurs in a ligand-independent manner. Since the downstream signalling repertoire of G protein signalling cascades depends on the receptor type and ligand (Kobilka et al., 1988; O'Dowd et al., 1988; Ostrowski et al., 1992), discovering both endogenous and synthetic ligands (i.e., de-orphanization) of the remaining ~150 orphan receptors would reveal their pharmacology and function, as well as pinpoint de-orphanized receptors as novel GPCR drug targets (Fredriksson et al., 2003; Hauser et al., 2017; Ngo et al., 2016).

1.3.2 Techniques for de-orphanization

1.3.2.1 Reverse pharmacology
Reverse pharmacology contributed towards the de-orphanization of orphan GPCRs. In general, reverse pharmacology involves identifying prospective ligands of orphan receptors, followed by an investigation of the pharmacological and physiological context via gene KO or overexpression of candidate orphan receptors (Kotarsky & Nilsson, 2004). There are three different strategies associated with reverse pharmacology in regards to de-orphanization (Kotarsky & Nilsson, 2004). The first method involves screening an extensive library of potential ligands against an orphan receptor library (Brown et al., 2003; Kotarsky & Nilsson, 2004). This technique screened a bank of prospective ligands in yeast and identified short chain fatty acids as agonists for orphans GPR41 and GPR43, both de-orphanized as free fatty acid receptor 3 and 2, respectively (Brown et al., 2003). Exposing cells that heterologously express candidate orphan receptors to fractionated tissue extracts containing prospective ligands is a defining characteristic of the second strategy i.e., “the orphan receptor strategy,” which led to the discovery of the neuropeptide orphanin FQ or nociceptin (Kotarsky & Nilsson, 2004; Lin & Civelli, 2004; Reinscheid et al., 1995). Lastly, the information based-approach, which
involves assessing activation by few prospective ligands from a previous database screening in a small subset of orphan GPCRs, contributed towards the identification of niacin receptor 2 in adipose tissues (Kotarsky & Nilsson, 2004; Tunaru et al., 2003). Traditional de-orphanization strategies of reverse pharmacology were successful in proposing orphan receptors as novel GPCR drug targets, but with the caveat of detecting changes on the second messenger level (Tang et al., 2012). Examples of second messenger assays include cytosolic Gq/Ca2+ transients, GTPγ binding or radioligand binding of G12/13, and modulation of cyclic adenosine monophosphate (cAMP) levels following Gi or Gs stimulation (Cerione et al., 1984; Lorenz et al., 1990; Stiles et al., 1984). However, some GPCR signalling pathways can occur independently of G proteins (Heuss et al., 1999; Tang et al., 2012). Therefore, more sufficient screening methods that detect “orphan receptor hits” via a G protein-independent approach are needed.

1.3.2.2 TANGO and PRESTO-TANGO assay

The recruitment of β-arrestin to the plasma membrane and co-localization with a ligand bound-receptor is characteristic of most GPCRs. In general, β-arrestin proteins (i.e., arrestin-1 – 4) bind to a phosphorylated GPCR, which leads to receptor desensitization and signalling attenuation (Shukla et al., 2011). The receptor-arrestin complex promotes GPCR internalization via clathrin-coated pit endocytosis and also acts as a scaffold to relay signals from the GPCR to another receptor or intracellular molecules (Luttrell et al., 1999; Shukla et al., 2011). Measuring β-arrestin recruitment is one way of detecting GPCR activation, and therefore, orphan receptor hits independent of G protein coupling.

The transcriptional activation following arrestin translocation (TANGO) assay depends on the binding of β-arrestin-2 (also known as arrestin-3) to the activated GPCR following ligand binding (Barnea et al., 2008). This assay involves the fusion of a GPCR with a transcriptional activator, which are separated by a cleavage site for a highly specific viral protease that is fused with β-arrestin (Figure 2) (Barnea et al., 2008). Ligand binding recruits β-arrestin-2 fused with the viral protease to the cleavage site, thereby allowing
the transcriptional activator to enter the nucleus to activate the luciferase reporter gene (Figure 2) (Barnea et al., 2008). The TANGO assay is advantageous when testing for potential ligands of orphan receptors whose second messenger signalling profiles remain unknown or weak. For instance, the structural similarity between chemokine-like receptor 1 (i.e., a leukocyte chemoattractant receptor) and the orphan receptor GPR1 led to the hypothesis that GPR1 responds to the leukocyte chemoattractant chemerin i.e., an endogenous ligand of chemokine-like receptor 1 (Barnea et al., 2008; Meder et al., 2003; Wittamer et al., 2003). In the TANGO assay, GPR1 responded to chemerin with EC\textsubscript{50} 240pM compared with 3nM for chemokine-like receptor 1, whereas chemerin-treatment to cells expressing GPR1 resulted in only intracellular Ca\textsuperscript{2+} levels 30% of that observed in cells expressing chemokine-like receptor 1 (Barnea et al., 2008). While independent of second messenger pathways, the TANGO assay is limited to screening GPCRs “one target at a time” and is unable to probe hundreds of GPCRs in a simultaneous fashion (Kroeze et al., 2015). An improved version of the TANGO assay is known as the, “Parallel Receptor-ome Expression and Screening via Transcriptional Output (PRESTO)-TANGO assay,” which facilitates the parallel and simultaneous profiling of prospective ligands across more than 300 human GPCRs (Kroeze et al., 2015).
Figure 2. Schematic representation of the TANGO assay.

Upon ligand binding to the GPCR fused with a transcriptional activator at the cystoplasmic tail (1), β-arrestin-2, with a viral protease attached, translocates to the cleavage site (2). This releases the transcriptional activator (3) to enter the nucleus to upregulate expression of the luciferase reporter gene (4). Figure created by JC with BioRender.
1.3.3 Lesser known and uncharacterized receptors: SUCNR1, CCRL2, GPR15, and GPR135

Pharmacological interventions and assays mentioned in previous chapters (i.e., treatment with the highly selective $G_q$ inhibitor YM or assessing for GPCR activation with the TANGO assay) are current methods that are used to further define the signalling profiles of lesser characterized and orphan GPCRs. Table 4 provides a list of four GPCRs—C-C chemokine receptor-like 2 (CCRL2), GPR15, succinate receptor 1 SUCNR1 (previously known as GPR91), and GPR135—and summarizes their tissue distribution profile, G-proteins they couple to, any putative and confirmed ligands, and physiological roles. These four GPCRs were selected as candidates for the tcLIGRLO-activated receptor from a pilot survey (unpublished data, Dr. McGuire) screen of >70 orphan GPCRs using the human orphan GPCR PathHunter ® (DiscoverX, San Francisco, CA) assay contract service.

1.3.3.1 SUCNR1: a de-orphanized receptor

Out of the four receptors in Table 4, SUCNR1 is the only de-orphanized receptor, with succinate as its only identified endogenous ligand to date (He et al., 2004). As well, it is the only receptor to have evidence of coupling to $G_i$ and $G_q$ (He et al., 2004; Robben et al., 2009). Blockade of the $G_q$ pathway with YM resulted in reduced Ca$^{2+}$ signalling in canine kidney cells following SUCNR1 stimulation by succinate (Robben et al., 2009). Similarly, treatment of human embryonic kidney 293 cells (HEK293) with a $G_i$ inhibitor led to reduced Ca$^{2+}$ signalling and inositol phosphate accumulation (He et al., 2004). In the study by He et al. (2004), intravenous injection of succinate into rats produced increased plasma levels of renin, which is an enzyme in the renin-angiotensin system that is responsible for regulating blood pressure. The association of SUCNR1 with blood pressure regulation proposes its role in modulating metabolic diseases (e.g., obesity, Type 2 diabetes mellitus, etc.). Thus, identifying another ligand in addition to succinate would provide a new avenue for investigating the downstream pathways following SUCNR1 activation.
1.3.3.2 The remaining orphans: CCRL2, GPR15, and GPR135

CCRL2, GPR15, and GPR135, are still classified as orphan GPCRs. Studies have identified ligands for CCRL2 and GPR15; however, these ligands are merely putative (Biber et al., 2003; Hartmann et al., 2008; Pan et al., 2017; Suply et al., 2017). The pending name for CCRL2 is, “atypical chemoattractant receptor 5,” due to its supposed role in scavenging and internalizing chemokine ligands via a G\textsubscript{i}-sensitive pathway in leukocytes (Biber et al., 2003; Leick et al., 2010). However, its additional role as a chemerin-presenting protein for chemokine receptor 1 via a G\textsubscript{i}-independent mechanism challenges its presumed classification as the fifth member of the atypical chemoattractant receptor family (Hartmann et al., 2008).

GPR15, which is differentially expressed in T-cell subtypes in humans (helper T cell) and mice (regulatory T cells and helper T cell 17), is reported to bind to GPR15L (i.e., a natural protein ligand expressed in skin and colon epithelium) to activate G\textsubscript{i}-signalling networks when homing T-cells to the colon (Suply et al., 2017). GPR15 is also reported to bind thrombomodulin. This interaction promotes angiogenesis by preventing the expression of apoptotic proteins in vascular endothelial cells (Pan et al., 2017). The thrombomodulin-activated GPR15 G-protein signalling is undetermined yet.

In comparison to CCRL2 and GPR15, GPR135 remains the most obscure out of the three orphan GPCRs. GPR135 is considered a prominent hypermethylation site in lung and ovarian cancers (Cardenas et al., 2014; Kettunen et al., 2017), but to date, it has no evidence of G-protein coupling or prospective ligand binding. GPR135 does heterodimerize with melatonin receptor 2 in a ligand-independent fashion (Watkins & Orlandi, 2020). Having no known endogenous ligand that readily activates GPR135, discovering potential synthetic ligands would reveal its downstream signalling network. In summary, prospective ligands for these four receptors—SUCNR1, CCRL2, GPR15, and GPR135—would advance understanding about their G protein signalling profiles, as well as propose novel roles for these four receptors during physical and disease processes.
Table 4. Summary table providing tissue distribution profile, G-protein signalling, putative ligands, and reported physiological roles of CCRL2, GPR15, SUCNR1, and GPR135

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Tissue distribution</th>
<th>G-protein signalling</th>
<th>Putative ligands</th>
<th>Physiological roles</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCRL2</td>
<td>Leukocytes</td>
<td>G\textsubscript{i} (Biber et al., 2003)</td>
<td>Chemokine ligand 2, 7, 8, 5, 19 (Biber et al., 2003)</td>
<td>Scavenge and internalize chemokine ligands (Leick et al., 2010)</td>
</tr>
<tr>
<td></td>
<td>(Suply et al., 2017)</td>
<td>G\textsubscript{i}-insensitive (Hartmann et al., 2008)</td>
<td>Chemerin (Hartmann et al., 2008)</td>
<td>Chemerin-presenting protein for chemokine receptor 1 (Hartmann et al., 2008)</td>
</tr>
<tr>
<td>GPR15</td>
<td>T-cell subsets in humans (helper T cell 12) and mice (regulatory T cells and helper T cell 17) (Nguyen et al., 2015)</td>
<td>G\textsubscript{i} (Suply et al., 2017)</td>
<td>GPR15L (Suply et al., 2017)</td>
<td>T-cell homing to colon (Suply et al., 2017)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not reported Thrombomodulin (Pan et al., 2017)</td>
<td></td>
<td>Endothelial cytoprotective function and</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Gene</th>
<th>Organs/Functions</th>
<th>G Proteins</th>
<th>Other Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUCNR1</td>
<td>Kidney, liver, spleen, immune cells, white adipose, retina (Toma et al., 2008)</td>
<td>G&lt;sub&gt;i&lt;/sub&gt; or G&lt;sub&gt;q&lt;/sub&gt; (He et al., 2004)</td>
<td>Succinate (He et al., 2004) Mediates metabolic conditions (e.g., hypertension, Type 2 diabetes mellitus, obesity, etc.) via renin-angiotensin system (He et al., 2004; Robben et al., 2009; Toma et al., 2008)</td>
</tr>
<tr>
<td>GPR135</td>
<td>Pituitary gland, eye, brain, stomach, testis (Fredriksson et al., 2003; Vanti et al., 2003)</td>
<td>Not reported</td>
<td>Heterodimerize with melatonin receptor 2 in a ligand-independent manner to mediate melatonin signalling (Watkins &amp; Orlandi, 2020) Hypermethylation target in cancers (e.g., lung and ovarian) (Cardenas et al., 2014; Kettunen et al., 2017)</td>
</tr>
</tbody>
</table>
1.4 Thesis statement, hypothesis, objectives, rationale

The working hypothesis for this thesis research is tcLIGRLO activates a GPCR G\textsubscript{q}-coupled signalling network to cause contraction of vascular smooth muscle in mouse femoral arteries (Figure 1).

The first aim of this thesis was:

1. To determine the effects of the G\textsubscript{q} inhibitor YM on tcLIGRLO-induced contractions. Experiments associated with this research objective employed wire myography to measure the functional response (i.e., contraction) of femoral arteries to tcLIGRLO. Considerations of the potential for sex- and age-related differences in tcLIGRLO responses were not explored in previous studies. Optimal conditions for such studies and effective inhibitor concentrations of YM needed to be determined for these assays. Therefore, we divided this research objective into two further sub-objectives:

   A. To assess the effect of sex and age on tcLIGRLO-induced contractions, which would help refine our choice of animal model and further optimize the assays of tcLIGRLO-elicited contractions.

   B. To determine the effects of the G\textsubscript{q} inhibitor YM on tcLIGRLO-induced contractions. We treated mouse femoral arteries ex vivo with YM using a range of concentrations based on published studies. We also tested the effects of YM on non-G\textsubscript{q} contractions stimulated by high extracellular K\textsuperscript{+} and the known G\textsubscript{q}-coupled \(\alpha\textsubscript{1}\)-adrenoreceptor type 1 using phenylephrine. We anticipated that YM would inhibit tcLIGRLO-mediated contractions. In separate studies, we conducted experiments in vitro to confirm YM inhibition of G\textsubscript{q}-Ca\textsuperscript{2+} signalling in vitro using tcLIGRLO and other PAR2APs with HEK293 cells expressing human PAR2.

The second aim was:

2. To assess the feasibility of using the TANGO assay to screen human GPCRs for potential tcLIGRLO targets.
A. To use tcLIGRLO and the other PAR2APs SLIGRL and 2fLIGRLO in the TANGO assay with cells expressing human PAR2. We expected to find that tcLIGRLO and the other PAR2APs would activate PAR2 in the assay.

B. To test tcLIGRLO in the TANGO assay with cells expressing other human GPCRs. A pilot survey of over 70 orphan GPCRs (McGuire, unpublished data) using a single dose of tcLIGRLO had identified several candidates. We used four candidate GPCRs (CCRL2, GPR15, SUCNR1, and GPR135) with available plasmid constructs for use in the PRESTO-TANGO kit. Amongst this selection, SUCNR1 is known to activate G_\text{q} signalling whereas less is known about G protein signalling by the other three GPCRs.
Chapter 2

2 Role of $G_q$ in tcLIGRLO-induced contractions of mouse vascular smooth muscle

2.1 Introduction

The PAR2AP tcLIGRLO activates PAR2 and one or more other receptors. These receptors remain unidentified (Chapter 1.3.3). tcLIGRLO causes vasoconstriction of mouse femoral arteries by stimulating a smooth muscle cell receptor that is distinct from PAR2 (Chapter 1.1). This contraction is dependent on the transient release of $Ca^{2+}$ from internal stores (Chapter 1.1). GPCR $G_q$ signalling pathways, including $Ca^{2+}$ transients, cause vascular smooth muscle contraction (Chapter 1.1). To date, the cyclodepsipeptide, YM, is one of the only known selective inhibitors of $G_q$ signalling (Chapter 1.2).

Inhibition of GPCR contraction of aortic ring preparations by treatments with YM has been used to demonstrate the critical role of $G_q$ in signalling by specific GPCRs (Table 3; Chapter 1.2.4).

We hypothesize that tcLIGRLO activates $G_q$-$Ca^{2+}$ signalling to contract mouse femoral arteries. The purpose of this study was to determine the effects of $G_q$ inhibition on tcLIGRLO-mediated contractions. We also tested the effects of YM on contractions mediated by the known $G_q$-coupled $\alpha_1$-adrenoreceptor type 1 with phenylephrine, and PAR2/$Ca^{2+}$ signalling stimulated by tcLIGRLO in HEK293 cells. The effects of subjects’ sex and age were also determined on baseline tcLIGRLO responses of mouse femoral arteries. The main finding of this study is tcLIGRLO contractions are mediated via $G_q$.

2.2 Materials and methods

2.2.1 Chemical reagents and drug solutions

Chemicals used to make Krebs buffer solutions were purchased from Bio Basic Inc. (Markham, ON) and Thermo Fisher Scientific (Mississauga, ON). YM (1mg) was purchased from Focus Biomolecules (Plymouth Meeting, PA) and was dissolved in
dimethyl sulfoxide to create stock solution of 2mM. The peptide tcLIGRLO was purchased from GenScript (Piscataway, NJ) and prepared as a 10 mM stock solution using 25mM HEPES buffer (pH 7.4). Phenylephrine was purchased from Bio Basic Inc. and was dissolved in double-distilled water. Acetylcholine (Ach) and sodium nitroprusside (SNP) were purchased from Sigma-Aldrich. Stock solutions were stored at -20 °C. Dilutions of stock solutions were prepared on the day of experiments.

2.2.2  Animals

2.2.2.1  Ethics Statement on the care and use of animals in research

All procedures for the care and use of animals in this study were approved by Western’s Institutional Animal Care Committee in accordance with the guidelines of the Canadian Council for Animal Care.

2.2.2.2  Mice

We used 31 systemic PAR2KO in substudy 1 and 2. For substudy 3, we used mice having homozygous floxed PAR2 alleles and a single copy Cre recombinase with expression regulated by the promoter for VE-cadherin. These mice are referred to as endothelial cell-specific PAR2 knockout (ecPAR2KO; n = 5). We used littermates (n=5) having genotypes that do not knockout PAR2 in endothelial cells as the controls, which are referred to as WT.

All the mice are from local colonies maintained and housed in the West Valley Barrier Facility at Western University. For the PAR2KO, the original breeders (Stock 4993) were three pairs of homozygous par2 KOs obtained from the Jackson Laboratory (Bar Harbor, ME) (Schmidlin et al., 2002). ecPAR2KO and WT strains were created at Western by Dr. McGuire lab with collaborators (Dr. Singh, Dr. Ramachandran).
2.2.3 Wire Myograph Experiments

Wire myography experiments using mouse femoral arteries were performed as described previously (McGuire et al., 2002). Procedures and protocols are outlined briefly in following section.

2.2.3.1 Isolation of femoral arteries

Mice were euthanized by cervical dislocation. Femoral arteries were isolated from hindlimb region of mice. Arterial ring preparations of mouse femoral arteries (two to four per mouse, 1.25 – 1.96 mm in length, 231 – 382 µm in diameter) were suspended by two stainless steel coated tungsten wires (40-µm diameter) between a micropositioner and force transducer in separate chambers of 620M Danish Myo Technology Multi Wire Myograph Systems (Hinnerup, DK). Each temperature (37°C) controlled chamber contained 5 mL Krebs buffer (pH 7.4) and was bubbled continuously with 95% O₂/5% CO₂ gas mixture. Krebs buffer was composed of (in mM): 118 NaCl, 4.7 KCl, 0.87 MgSO₄, 0.86 KH₂PO₄, 2.5 CaCl₂, 10 D-glucose, 25 NaHCO₃, and 25 HEPES.

2.2.3.2 DMT myographs

DMT force transducers were frequently calibrated according to manufacturer’s instructions. During each experiment, isometric tension measurements were recorded continuously using a computer (Microsoft Windows operating system) with the LabChart software (AD Instruments; Dunedin, NZ).

2.2.3.3 Normalization of baseline tension for femoral arteries

A resting baseline tension was set by stretching each arterial ring along their short-axis (radii) to an optimized internal diameter under isometric tension conditions. In brief, we used the normalization protocol for setting resting tension of small arteries described by (Mulvany & Halpern, 1976). From a starting point with no tension applied, the small arterial rings were stretched to an internal circumference IC₁, which is a fraction (normalization factor) of the internal circumference (IC₁₀₀) that is estimated from length-
tension measurements to produce a target transmural pressure. The normalization parameters used in the calculations for the mouse femoral arteries in this study were: target transmural pressure = 13.3kPa; IC$_1$/IC$_{100}$= 0.9 (Normalization factor). Calculations of IC$_1$ and IC$_{100}$ were determined using the DMT Normalization plug-in for LabChart software (AD Instruments; Dunedin, NZ), which interpolates the IC$_{100}$ from a curve fit of length (diameter)-tension (mN/wall length) relationship data using equations derived from the Law of LaPlace. The formulas are modified to account for the elliptical circumference of the mounted vessels and the diameter of the mounting wires. The long axis of the mounted vessels was measured at 40X magnification using a calibrated ocular eyepiece (2mm/number ocular divisions) in a binocular dissection microscope (wall length = 2 x artery long axis length). For each arterial ring, length-tension relationships were determined by step wise moving the distance between the mounting wires and recording the tension for 90s. Sufficient data points to interpolate the IC$_{100}$ value from a curve fit of the data were acquired. Femoral arteries were equilibrated at the optimized resting tension for 30 – 40 min prior to the bioassay protocols.

2.2.3.4 Vascular smooth muscle contraction and relaxation bioassay protocols

Arterial rings were exposed to KCl (30, 60, 90 mM) to test viability. Tissues producing <1.5mN were excluded from this study. Arteries were exposed to a 20 – 30-min washout period before conducting further studies. Table 5 is organized according to substudies 1 – 3 and provides a list of physical characteristics of mice, blood vessel dimensions, and sample size of the different treatments.

Substudy 1: Sex and age in PAR2KO mice
tcLIGRLO dose-response curves (10, 20, 30µM) were constructed with PAR2KO mice. Mice were grouped by sex (males n=18; females n=3). Data from male mice were binned by age groups 20-25, 30-35, and 35-40 weeks. We assessed endothelium-dependent relaxation with Ach (0.001 – 30µM) and endothelium-independent relaxation with SNP (0.001 – 30µM) in vessels from male mice after their vessels were pre-contracted with
3µM phenylephrine. Phenylephrine (0.001 – 10µM) was added to femoral arteries from male and female mice. Tissues were exposed to a 30-min washout period between each dose-response curve.

**Substudy 2: Effects of YM on femoral arteries from PAR2KOs**

**Substudy 2.1. tcLIGRLO and YM**

An additional tcLIGRLO dose-response curve (0.5 – 50µM) was performed with femoral arteries from male mice (n=4). Following a 30-min washout period, different concentrations of YM (10, 30, 100 nM) were added to each channel. YM was incubated with the tissues in each channel for 15 min prior to repeating the tcLIGRLO dose-response curve.

**Substudy 2.2. Phenylephrine and YM**

In a separate study, phenylephrine dose-response curves (0.001 – 10µM) in combination with YM was performed with male mice using the same protocol from substudy 2.1.

**Substudy 2.3. KCl and YM**

With the mice cohort from substudy 1, after a 30-min washout period, different concentrations of YM (control, 10, 30, 100nM) were added to each channel 15 min prior to treating tissues with 90mM KCl.

**Substudy 3: ecPAR2KO**

**Substudy 3.1. tcLIGRLO dose-response curves**

tcLIGRLO dose-response curves (10, 20, 30µM) were performed with ecPAR2KO (n=5) and PAR2WT mice (n=5).

**Substudy 3.2. Ach and SNP relaxation**

After a 30-min washout period following treatment of vessels with tcLIGRLO, endothelium-dependent and -independent relaxation were assessed with Ach (0.001 –
30µM) and SNP (0.001 – 30µM), respectively. A 30-min washout period was performed between each dose-response curve.

### 2.2.4 Cell lines

Cell lines and cell culture reagents were purchased from Thermo Fisher Scientific. PAR2KO HEK293 were generated using CRISPR/Cas9 targeting as described (Sanjana et al., 2014; Shalem et al., 2014; Thibeault & Ramachandran, 2020). Normal HEK293 were referred to as PAR2WT cells. The PAR2 gene sequence (CCCCAGCAGCCACGCCGCGC) was cloned into the lentiCRISPR v2 plasmid (Addgene plasmid no. 52961). Approximately 48h after transfection, PAR2-deficient cells were selected in media containing puromycin (5µg/mL). PAR2WT HEK293 and PAR2KO HEK293 were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 1% sodium pyruvate, and penicillin streptomycin solution (50 000 units penicillin, 50 000µg streptomycin). Since trypsin activates PAR2, cells were routinely subcultured with enzyme-free isotonic phosphate-buffered saline (PBS) containing EDTA (1mM).

### 2.2.5 Ca²⁺ signalling

We measured whole cell Ca²⁺ transients in PAR2WT HEK293 and PAR2KO HEK293 cell suspensions using a Photon Technology International QuantaMaster 800 spectrophotometer (Birmingham, NJ) as described (Thibeault & Ramachandran, 2020). Once cells reached 70-80% confluency in a T-25 flask, they were detached in enzyme-free cell dissociation buffer, centrifuged with Eppendorf™ 5804R with a S-4-72 rotor (1000 rpm, 5 min), to attain a pellet and re-suspended in 1mL of Fluo-4 no wash Ca²⁺ indicator dye (Thermo Fisher Scientific) for 30 min at room temperature. 2mL of cell suspension was added to each cuvette and intracellular dye fluorescence (excitation, 488nm; emission, 506 nm) was monitored before and after the addition of tcLIGRLO to PAR2WT HEK293 (1-100µM tcLIGRLO) and PAR2KO HEK293 (30µM tcLIGRLO) at room temperature (20°C). YM (0.03 – 1µM) was added to cuvettes containing cells 10
min prior to adding tcLIGRLO (30µM) in PAR2WT cells at room temperature. Each cuvette was read for 2 min before changing to the next cuvette.

2.2.6 Data analysis and statistics.

Data are reported as mean ± standard error of mean (S.E.; error bars) in graphs and Tables. n indicates number of mice per group or number of independent experiments with cells. Arterial ring contractions produced by cumulative concentrations of tcLIGRLO and phenylephrine are reported as a percentage of 90mM KCl contractions. The maximum effect (E\textsubscript{max}) for each agonist was determined from the concentration (dose)-response curves (CRCs) for each treatment and mouse. YM inhibition of agonist responses were calculated from agonist responses prior to and after pretreatment with YM. Ach and SNP-induced relaxations (Relaxation (%)) were determined by the reversal of the tone produced by 3µM phenylephrine. EC\textsubscript{50} values (concentration producing 50% of E\textsubscript{max}) for agonists were estimated from best-fit sigmoidal dose response curves based on nonlinear regression of the group mean data. pEC\textsubscript{50} is -log\textsubscript{10} EC\textsubscript{50} (M). Ca\textsuperscript{2+}-dye fluorescence changes to agonists were normalized to an internal control, the Ca\textsuperscript{2+} ionophore A23187 (3µM; Sigma-Aldrich).

Statistical analyses were performed in GraphPad Prizm v.9.2.0. Correlation between tcLIGRLO responses and age was tested using linear regression test. F-test was used to compare the slope to non-zero value. E\textsubscript{max} were compared between groups by unpaired Student’s t-test or one-way analysis of variance calculations (ANOVA) followed by Bonferroni post hoc. F-test was used to compare the curves for differences in EC\textsubscript{50} or IC\textsubscript{50} as applicable. tcLIGRLO dose-response data from ecPAR2KO and WT mice were compared by two-way ANOVA followed by Bonferroni post hoc. *p<0.05 was considered significant for all comparisons.
Table 5. A summary table of physical characteristics of mice (weight and age) and femoral arteries (length and diameter) and sample size

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Weight (g)</th>
<th>Age (weeks)</th>
<th>Tissue length (mm)</th>
<th>Diameter (µm)</th>
<th>Sex (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Substudy 1: Sex and age in PAR2KO mice</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tcLIGRLO&lt;sup&gt;a&lt;/sup&gt;</td>
<td>30.7±0.9</td>
<td>32.0±2.8</td>
<td>1.55±0.01</td>
<td>310±9</td>
<td>Males (18)</td>
</tr>
<tr>
<td></td>
<td>25.3±3.8</td>
<td>31.8±5.3</td>
<td>1.57±0.09</td>
<td>318±25</td>
<td>Females (3)</td>
</tr>
<tr>
<td><strong>Ach&lt;sup&gt;b&lt;/sup&gt;</strong></td>
<td>30.8±2.9</td>
<td>37.7±1.3</td>
<td>1.63±0.16</td>
<td>317±14</td>
<td>Males (4)</td>
</tr>
<tr>
<td><strong>SNP&lt;sup&gt;c&lt;/sup&gt;</strong></td>
<td>30.4±3.1</td>
<td>36.9±1.7</td>
<td>1.50±0.30</td>
<td>327±34</td>
<td>Males (7)</td>
</tr>
<tr>
<td><strong>Phenylephrine&lt;sup&gt;b&lt;/sup&gt;</strong></td>
<td>23.8±0.4</td>
<td>32.4±1.7</td>
<td>1.66±0.20</td>
<td>310±7</td>
<td>Males (3)</td>
</tr>
<tr>
<td></td>
<td>27.8±2.2</td>
<td>21.4±2.8</td>
<td>1.47±0.06</td>
<td>270±28</td>
<td>Females (3)</td>
</tr>
<tr>
<td><strong>Substudy 2: YM inhibition in PAR2KO mice</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tcLIGRLO&lt;sup&gt;d&lt;/sup&gt;</td>
<td>30.0±0.6</td>
<td>22.6±0.3</td>
<td>1.60±0.10</td>
<td>280±8</td>
<td>Males (4)</td>
</tr>
<tr>
<td><strong>Phenylephrine&lt;sup&gt;c&lt;/sup&gt;</strong></td>
<td>29.9±3.7</td>
<td>32.5±7.3</td>
<td>1.53±0.14</td>
<td>317±48</td>
<td>Males (12)</td>
</tr>
<tr>
<td><strong>90mM KCl</strong></td>
<td>30.3±3.1</td>
<td>31.5±3.8</td>
<td>1.57±0.13</td>
<td>317 ±32</td>
<td>Males (10)</td>
</tr>
</tbody>
</table>
Substudy 3: ecPAR2KO

<table>
<thead>
<tr>
<th>tcLIGRLO(^a), Ach(^b)/SNP(^c) in ecPAR2KO mice</th>
<th>25.1±1.2</th>
<th>19.4±1.2</th>
<th>1.57±0.09</th>
<th>306±9</th>
<th>Males (^f) (2), Females (3)</th>
</tr>
</thead>
</table>

| tcLIGRLO\(^a\), Ach\(^b\)/SNP\(^c\) in PAR2WT mice | 25.1±1.7 | 19.0±0.7 | 1.48±0.07 | 260±28 | Males (4), Females \(^f\) (1) |

No differences were detected for weight, age, tissue length, and diameter between sex (p>0.05; unpaired Student’s \(t\)-test) and treatment groups (p>0.05; One-way ANOVA)

a, 10 – 30\(\mu\)M; b, 0.001 – 10\(\mu\)M; c, 0.001 – 30\(\mu\)M; d, 0.5 – 50\(\mu\)M; e, mean±SD; f, was pooled with matched sex because sample size was <3

33
2.3 Results

2.3.1 Effects of sex and age on tcLIGRLO-induced contractions

tcLIGRLO produced concentration-dependent contractions of femoral arteries from male PAR2KO (Figure 3, Table 6). tcLIGRLO dose-response curves did not differ between males and females (Figure 4, Table 6). K⁺-induced contractions, which were used to normalize the tcLIGRLO data between experiments, did not differ between sexes (inset Figure 4B). Phenylephrine was more potent in femoral arteries of female versus male PAR2KO, as demonstrated by a leftward shift of the curve for females and a 10-fold difference in EC₅₀ values (Figure 5, Table 6). Phenylephrine produced larger Eₘₐₓ contractions in male than female PAR2KO arteries by nearly 30% (Figure 5, Table 6). K⁺-induced contractions prior to phenylephrine-treatments did not differ between sexes (inset Figure 5B). tcLIGRLO-induced contractions exhibited a significant negative linear correlation to age despite its low r² value 0.20 (inset Figure 7C). When data were binned according to age categories of approximate equal sizes, we found the magnitude of contractions were larger in arteries from the youngest age group mice (20 – 25 weeks, Figure 7A, Table 7) by ≥50% from the 30 – 35 weeks and nearly 30% from the 35 – 40 weeks age group. Baseline contractions to K⁺ prior to tcLIGRLO contractions did not differ between age groups (Figure 7B). Figure 6 shows the endothelium-dependent and -independent relaxation of femoral arteries from PAR2KO mice. (Figure 4, Table 6).
Figure 3. tcLIGRLO-induced contractions of femoral arteries from male PAR2KO mice.

Femoral arteries were given 0.5µM – 50µM of tcLIGRLO to produce contractions, which were normalized by 90mM KCl-treatment. A representative recording of isometric tension experiment showing contractions produced by the addition of KCl (A) and tcLIGRLO (B) is provided. C. \( E_{\text{max}} \) and \( \text{pEC}_{50} \) are provided in Table 6. Nonlinear regression curve fit is shown as mean ± S.E. (error bars) for subjects (n=4). N.B. the response to the highest dose of tcLIGRLO (50 µM) was determined in two samples, as indicated by parentheses.
Femoral arteries from both sexes were treated with 10, 20, and 30µM tcLIGRLO to produce contractions, which were normalized against baseline contraction values from 90mM K⁺-treatment. $A$. $E_{\text{max}}$ and $pEC_{50}$ are provided in Table 6. There were no differences between means of $E_{\text{max}}$ ($p>0.05$; Unpaired Student’s $t$-test) and $EC_{50}$ values ($p>0.05$; F-test). Nonlinear regression curve fit is shown as mean ± S.E. $N.B$. Sample size for females was a lot smaller due to limited availability of mice during breeding.
Figure 5. Phenylephrine CRCs in male vs female PAR2KO femoral arteries.

Femoral arteries from both sexes were treated with 0.01 – 10µM of phenylephrine to produce contractions, which were normalized against baseline contraction values from 90mM K⁺-treatment. A. E\textsubscript{max}\textsuperscript{a} (*p<0.05; Unpaired Student’s t-test) and pEC\textsubscript{50}\textsuperscript{b}(*p<0.05; F-test) are provided in Table 6. Inset B. Contractions to 90mM K⁺-treatment between male and female mice were not significantly different from each other (p>0.05; Unpaired Student’s t-test).
Figure 6. Ach and SNP-relaxation response curves in femoral arteries from male PAR2KO mice.

Relaxation responses to 3µM phenylephrine using 0.001 – 10µM Ach (A; n=4) and 0.001 – 30µM SNP (B; n=7) were performed following tcLIGRLO-treatment. Nonlinear regression curve fit is shown as mean ± S.E. (error bars).
Table 6. A summary table of pEC\textsubscript{50}, E\textsubscript{max}, and sample size values of tcLIGRLO and phenylephrine drug treatments in PAR2KO mice.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>pEC\textsubscript{50} (M)</th>
<th>E\textsubscript{max}(M)</th>
<th>Sex (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>tcLIGRLO\textsuperscript{a}</td>
<td>5.41±0.02</td>
<td>114±1</td>
<td>Males (4)</td>
</tr>
<tr>
<td>tcLIGRLO\textsuperscript{b}</td>
<td>4.85±0.03</td>
<td>56±6</td>
<td>Males (18)</td>
</tr>
<tr>
<td></td>
<td>4.88±0.02</td>
<td>74±27</td>
<td>Females (3)</td>
</tr>
<tr>
<td>Ach\textsuperscript{c}</td>
<td>7.61±0.10</td>
<td>78±17</td>
<td>Males (4)</td>
</tr>
<tr>
<td>SNP\textsuperscript{d}</td>
<td>7.78±0.02</td>
<td>100±0</td>
<td>Males (7)</td>
</tr>
<tr>
<td>Phenylephrine\textsuperscript{e}</td>
<td>6.49±0.04</td>
<td>113±6</td>
<td>Males (3)</td>
</tr>
<tr>
<td></td>
<td>7.45±0.09*</td>
<td>84±7*</td>
<td>Females (3)</td>
</tr>
</tbody>
</table>

*p<0.05 with F-test (pEC\textsubscript{50}) and unpaired Student’s t-test (E\textsubscript{max}), males vs. females.

a, 0.5 – 50µM; b, 10 – 30µM; c, 0.001 – 10µM; d, 0.001 – 30µM
Figure 7. Effect of age on tcLIGRLO contractions of male PAR2KO femoral arteries.

$E_{\text{max}}$ of tcLIGRLO-induced contractions were normalized relative to baseline contractions values at 90mM K$^+$-treatment. Mice were grouped into three different age groups—20 – 25 weeks (n=5), 30 – 35 weeks (n=7), and 35 – 40 weeks (n=9). Data are reported as mean ± S.E. (error bars). A. A summary table of mean $E_{\text{max}}$ values of the three different age groups is shown in Table 7. Significance (*p<0.05) was determined by one-way ANOVA followed by Bonferroni post hoc. B. Contractions to 90mM K$^+$-treatment between age groups were not significantly different from each other (p>0.05; One-way ANOVA). *Inset C. Equation for linear graph is $y=-2.4x+158.0$. Slope of $E_{\text{max}}$ demonstrates a significant negative correlation to age (*p<0.05; F-test) with $r^2$=0.20.
Table 7. $E_{\text{max}}$ values of tcLIGRLO-mediated contractions of male PAR2KO femoral arteries from three age groups

<table>
<thead>
<tr>
<th>Age group (weeks)</th>
<th>n</th>
<th>$E_{\text{max}}$ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-25</td>
<td>5</td>
<td>101 ± 16*</td>
</tr>
<tr>
<td>30-35</td>
<td>7</td>
<td>42 ± 11</td>
</tr>
<tr>
<td>35-40</td>
<td>9</td>
<td>73 ± 6</td>
</tr>
</tbody>
</table>

$E_{\text{max}}$ values of tcLIGRLO-mediated contractions were recorded at 30µM tcLIGRLO. *p<0.05, compared to 30 – 35 weeks; One-way ANOVA followed by Bonferroni post hoc

a, mean±SEM
2.3.2. Effects of the $G_q$ inhibitor YM on femoral arteries

To determine the role of $G_q$ in tcLIGRLO-induced contractions, we incubated femoral arteries with YM for 15 min before adding tcLIGRLO (Figure 8, Table 8). We found that 10 and 30nM of YM did not inhibit tcLIGRLO-mediated contractions, while 100nM YM abolished contractions. Similarly, in pilot experiments where we pre-treated mouse femoral arteries with YM for 30 min (n=2), 10 and 30 nM of YM also did not induce inhibition, while 100nM YM completely inhibited tcLIGRLO-mediated contractions. We also tested the effect of YM on phenylephrine CRCs (Figure 9, Table 8). We found that all doses of YM inhibited phenylephrine-induced contractions, with complete abolishment of contractions at 100nM YM. K+ contractions of YM-treated arteries did not differ from untreated arteries (Figure 10).
Figure 8. YM inhibition of tcLIGRLO-mediated contractions in femoral arteries of PAR2KO male mice.

Contractions to 0.5 – 50µM tcLIGRLO were normalized relative to the maximum contractions at 50µM tcLIGRLO prior to 15-min pre-treatment of YM. Table 8 provides E\text{\textsubscript{max}} and pEC\textsubscript{50} values of tcLIGRLO-mediated contractions. 100nM YM completely abolished tcLIGRLO-mediated contractions as compared with untreated arteries (*p<0.05; F-test). E\text{\textsubscript{max}} values did not differ between groups in both data sets in control vs. 10nM YM and control vs. 30nM YM (p>0.05; One-way ANOVA). 10nM and 30nM YM failed to inhibit tcLIGRLO-mediated contractions as compared with control (p>0.05; F-test). Nonlinear regression curve fit is shown as mean ± S.E. (error bars). N.B. only two mice were done for the highest dose of tcLIGRLO (50µM), as indicated by parentheses. Numbers within parentheses beside respective group indicate number of animals used.
Figure 9. YM inhibition of phenylephrine-mediated contractions in femoral arteries of PAR2KO male mice.

Contractions to 0.001 – 10µM phenylephrine were normalized relative to the maximum contractions at 10µM phenylephrine prior to 15-min pre-treatment of YM. Table 8 provides $E_{\text{max}}$ and pEC$_{50}$ values of contractions. 100nM YM completely abolished phenylephrine-mediated contractions as compared with untreated arteries (*p<0.05; F-test). Both 10nM and 30nM YM inhibited phenylephrine-induced contractions, as demonstrated by significant rightward shift in EC$_{50}$ values in comparison to control (*p<0.05; F-test). Nonlinear regression curve fit is shown as mean ± S.E. (error bars).
Table 8. $E_{\text{max}}$ and $pEC_{50}$ values of tcLIGRLO- and phenylephrine-induced contractions following YM treatments in femoral arteries from male PAR2KO mice.

<table>
<thead>
<tr>
<th></th>
<th>control&lt;sup&gt;a,b&lt;/sup&gt;</th>
<th>YM 10nM&lt;sup&gt;a,c&lt;/sup&gt;</th>
<th>YM 30nM&lt;sup&gt;a,d&lt;/sup&gt;</th>
<th>YM 100nM&lt;sup&gt;a,d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>tcLIGRLO&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$E_{\text{max}}$ (%)</td>
<td>60±11</td>
<td>87±1</td>
<td>83±14</td>
<td>0*</td>
</tr>
<tr>
<td>$pEC_{50}$ (M)</td>
<td>5.30±0.02</td>
<td>5.17±0.02</td>
<td>5.22±0.03</td>
<td>--</td>
</tr>
<tr>
<td>Phenylephrine&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$E_{\text{max}}$ (%)</td>
<td>115±15</td>
<td>92±3</td>
<td>87±17</td>
<td>0*</td>
</tr>
<tr>
<td>$pEC_{50}$ (M)</td>
<td>6.45±0.02</td>
<td>6.13±0.05*</td>
<td>6.00±0.04*</td>
<td>--</td>
</tr>
</tbody>
</table>

Femoral arteries were treated with tcLIGRLO and phenylephrine to determine effects of YM inhibition. *p<0.05, treatment compared to control; F-test

a, tcLIGRLO-treatment n=4; b, phenylephrine-treatment n=12; c, phenylephrine-treatment n=10; d, phenylephrine-treatment n=7; e, 0.5 – 50µM; f, mean±SEM ; g, 0.001 – 10µM
Figure 10. K⁺ contractions in the presence and absence of YM.

Contractions to 90mM K⁺ of arteries treated with 0 (control), 10, 30, and 100nM YM were normalized to 90mM K⁺ determined by a K⁺ dose-response curve for each artery. Data are reported as mean ± S.E. (error bars). K⁺ contractions of YM treated arteries did not significantly differ from untreated arteries (p>0.05, one-way ANOVA). Numbers within parentheses beside respective group indicate number of animals used.
2.3.2 tcLIGRLO effects in ecPAR2KO mice

tcLIGRLO- and K+-induced contractions of femoral arteries in ecPAR2KO did not differ from WT (Figure 11A and Inset B). Endothelium-dependent and -independent relaxations of femoral arteries did not differ between ecPAR2KO and WT (Figure 12A and B, Table 9).
Figure 11. tcLIGRLO-mediated contractions in ecPAR2KO and PAR2WT femoral arteries.

A. Under baseline conditions, arteries were treated with 10, 20, and 30µM tcLIGRLO. Data points are the tcLIGRLO contractions normalized to 90 mM K⁺ contractions (Inset B). tcLIGRLO-induced contractions did not significantly differ between strains (p>0.05; two-way ANOVA). Contractions to 90mM K⁺-treatment also did not significantly differ between strains (p>0.05; unpaired Student’s t-test). Eₘₐₓ and pEC₅₀ values are given by Table 9. Nonlinear regression curve fits were done via F-test. Data points are mean ± S.E. (error bars). Numbers within parentheses indicate the sample size (number of animals) for each group.
Figure 12. Ach- and SNP CRCs in ecPAR2KO and PAR2WT femoral arteries.

Relaxation responses to 0.001 – 10µM Ach (A) and 0.001 – 30µM SNP (B) induced by 3µM phenylephrine pretreatment are provided. $E_{\text{max}}$ and pEC$_{50}$ values are given by Table 8. Nonlinear regression curve fits were performed via F-test. Data points are mean ± S.E. (error bars). Numbers within parentheses indicate the sample size (number of animals) for each group.
Table 9. pEC$_{50}$ and $E_{\text{max}}$ values of Ach- and SNP-induced relaxation in femoral arteries from ecPAR2KO and WT mice following pre-contraction to 3µM phenylephrine.

<table>
<thead>
<tr>
<th></th>
<th>ecPAR2KO$^b$</th>
<th>WT$^c$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$E_{\text{max}}^d$ (%)</td>
<td>84±6</td>
<td>85±4</td>
</tr>
<tr>
<td>pEC$_{50}^d$ (M)</td>
<td>7.86±0.12</td>
<td>8.29±0.16</td>
</tr>
</tbody>
</table>

SNP$^e$

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$E_{\text{max}}^d$ (%)</td>
<td>98.4±0.5</td>
<td>97±2</td>
</tr>
<tr>
<td>pEC$_{50}^d$ (M)</td>
<td>8.08±0.07</td>
<td>8.11±0.10</td>
</tr>
</tbody>
</table>

Ach CRCs were conducted following a 30-min washout period subsequent to tcLIGRLO contractions. After another 30-min washout period, SNP CRCs were performed. There were no differences in $E_{\text{max}}$ (p>0.05; unpaired Student’s $t$-test) and pEC$_{50}$ values (p>0.05; F-test) between strains.

a, 0.001 – 10µM; b, n=5; c, n=5; d, mean±SEM; e, 0.001 – 30µM
2.3.3 Effects of the G<sub>q</sub> inhibitor YM on Ca<sup>2+</sup> signals in PAR2WT HEK293 cells

To confirm inhibition of G<sub>q</sub>-coupled Ca<sup>2+</sup> signals by YM, we first assessed Ca<sup>2+</sup> signalling with 30µM tcLIGRLO using PAR2WT HEK293 (Figure 13B and C). Following that, we assessed tcLIGRLO-induced Ca<sup>2+</sup> signals at four different incubation periods with YM (0, 5, 20, 30 min; Figure 14). We found that 1µM YM abolished tcLIGRLO-mediated Ca<sup>2+</sup> signals at 20 min. The incubation time of 30 min also abolished Ca<sup>2+</sup> signals, but we noted that one of the replicates showed less inhibition. 30µM tcLIGRLO did not activate Ca<sup>2+</sup> signals in PAR2KO HEK293 cells (Figure 13A). This result validated the specificity of tcLIGRLO for PAR2 in vitro (Figure 13A and C). Thrombin elicited a Ca<sup>2+</sup> signal in PAR2KO HEK293 which shows the cells were viable and responsive to other GPCR, specifically PAR1 in these cells, activations. After treating cells with increasing concentrations of YM for 10 min, YM inhibited tcLIGRLO-induced PAR2-Ca<sup>2+</sup> signalling, with a pIC<sub>50</sub> value of 6.85±0.08M (Figure 15).
Figure 13. tcLIGRLO-mediated Ca^{2+} signalling in PAR2KO and PAR2WT HEK293 cells.

Representative data recordings of 30µM tcLIGRLO-mediated Ca^{2+} signalling in PAR2KO (A) and PAR2WT HEK293 cells (B) are provided. C. Ca^{2+} signalling in response to drugs (thrombin, tcLIGRLO, and YM) was normalized to Ca^{2+} response to ionophore (3µM; A23187). A. Thrombin (100µM) was added to ensure the presence of PAR1 in PAR2KO HEK293 cells. C. When treating PAR2KO cells (n=3) with 100µM thrombin, this resulted in 47±17% Ca^{2+} signalling, while 30µM tcLIGRLO failed to induce any response. Treatment of HEK293 cells (n=3) with 30µM tcLIGRLO resulted in a 42±3% Ca^{2+} response. Significance (*p<0.05) was determined via unpaired Student’s t-test. Data are reported as mean ± S.E. (error bars).
Figure 14. YM inhibition of PAR2-activated Ca$^{2+}$ signalling for tcLIGRLO-treated PAR2WT HEK293 cells.

HEK293 cells (n=3) were incubated with 1µM YM at different incubation time points (0, 5, 20, and 30 min) prior to tcLIGRLO-treatment. Data are reported as mean ± S.E. (error bars). Nonlinear regression curve fit is shown as mean ± S.E. (error bars).
Figure 15. tCLIGRLO-mediated Ca\(^{2+}\) signalling in PAR2WT HEK293 cells.

Inhibitory dose response curve with 10 min pre-treatment of 0.003 – 1µM YM of 30µM tCLIGRLO-mediated Ca\(^{2+}\) signalling in PAR2WT HEK293 (n=3) cells is shown. \(E_{\text{max}}\) signal for tCLIGRLO relative to A23187 and \(pIC_{50}\) value for YM inhibition of tCLIGRLO signal are reported as mean±SEM. Nonlinear regression curve fit is shown as mean ± S.E. (error bars).
2.4 Discussion

The main finding of this study are age-related effects and a link to $G_q$-coupling in tcLIGRLO-mediated contractions in mouse femoral arteries. Results from this study will contribute towards the further delineation of the signal transduction profile that mediate contractions elicited by tcLIGRLO.

2.4.1 Age-related effects on tcLIGRLO-mediated contractions

Risk factors that compromise vascular health on the morphological and structural level of arteries include age and sex. In particular, the human ageing process is marked by an imbalance of vasoconstrictor and vasodilator molecules (e.g., nitric oxide) in the endothelium (i.e., endothelial dysfunction) (Brandes et al., 2005; Herrera et al., 2010), as well as an increased ratio of collagen to elastin in the extracellular matrix due to elastin fragmentation (Duca et al., 2016; Greenwald, 2007; Sehgel et al., 2015). Here, we looked at age as a factor that affects tcLIGRLO-induced contractions in mouse femoral arteries and discovered a novel $G_q$-mediated vasoconstrictor mechanism.

The tcLIGRLO-activated receptor is reported to be in the smooth muscle of mouse femoral arteries (McGuire et al., 2002). We found that the magnitude of tcLIGRLO-induced contractions exhibited a negative linear correlation to increasing age (Figure 8). There was a significant reduction in tcLIGRLO-induced contractions following 25 weeks, specifically between the age groups 20-25 weeks and 30-35 weeks. However, we note a gap in data covering the age range from 25-30 weeks and overall a more narrow age range (20-40 weeks) than studies by Seawright et al. (2016, 2018). In those studies using 16 and 96 weeks of age rats, various GPCR ligands including norepinephrine, phenylephrine, and angiotensin II were tested and their contractions of soleus muscle feed arteries were reduced in the older rats. Interestingly, age-related effects in smooth muscle contractions induced by norepinephrine disappeared upon endothelium denudation, whereas reduced vasoconstrictor responses to phenylephrine and angiotensin II were still apparent in aged vessels (Seawright et al., 2018). Preserved contractions to
norepinephrine in denuded vessels suggest that decreased norepinephrine-induced constrictions in aged, intact arteries are due to endothelial dysfunction. In contrast, age-induced decline in constrictions stimulated by phenylephrine and angiotensin II in both intact and denuded arteries are predominantly due to reduced vascular smooth muscle function from ageing effects.

Studies have pointed to increased vascular stiffness during the ageing process as one of the reasons for diminished vasoconstrictor responses (Duca et al., 2016; Greenwald, 2007; Seawright et al., 2018; Sehgel et al., 2015). More specifically, a heightened vascular stiffness is attributed to an increased expression of adhesion molecules such as α1β1 (Seawright et al., 2018; Sehgel et al., 2015) in compensation for reduced proteins essential for smooth muscle contractions (e.g. vinculin and pFAK397) in old versus young vessels (Seawright et al., 2018). Additional experiments involving endothelium denudation are needed to comment on the interplay between the endothelium and smooth muscle in tcLIGRLO-mediated contractions.

We did not detect sex differences in tcLIGRLO-mediated contractions of femoral arteries in PAR2KO. In our experiments using phenylephrine with PAR2KO femoral arteries, arteries from females were initially more sensitive to α1 adrenergic receptor activation in comparison to male arteries, as demonstrated by the leftward shift in EC\text{50} values experienced by female arteries by nearly 10 folds (Table 6). As shown by their E\text{max} values, arteries from male mice managed to surpass contractions experienced by female arteries by almost 30% at higher concentrations (>0.3µM; Table 6). Younger human males are reported to initially exhibit higher levels of α1 adrenergic reactivity, while human females experience an increased sensitivity to phenylephrine later on in life (Aloysius et al., 2012; Keung et al., 2005; Turner et al., 1999). Considering the age difference in the male and female PAR2KO mice (21±3 weeks vs. 32±2 weeks), there is potential for an interaction between sex and age to influence contractions due to declining levels of estrogen with increasing age in our mouse models (McNeill et al., 2002; Novella et al., 2012; Turner et al., 1999). Estrogen is known as a protective agent against
cardiovascular disease by promoting the expression of eNOS, thus increasing nitric oxide production levels (McNeill et al., 2002; Novensà et al., 2011). Novensà et al. (2011) found that an increased estrogen receptor β to α ratio in aged female mice may be linked to oxidative stress, which likely contributes to higher vasoreactivity in older females. Altogether, tcLIGRLO-mediated contractions did not differ between sexes, but did decrease with increasing age of mice.

2.4.2 tcLIGRLO-mediated contractions are G_q-dependent

tcLIGRLO-mediated contractions are dependent on the transient release of Ca^{2+} from internal stores (Chapter 1.1), leading us to test the role of G_q. In our experiments with tcLIGRLO and PAR2KO femoral artery contractions, 100nM of YM, a highly specific G_q-inhibitor (Chapter 1.2), abolished tcLIGRLO-mediated contractions (Figure 1; Chapter 1). The specificity of YM’s effect on G_q-coupled contractions was confirmed by its inhibitory effect on phenylephrine (Figure 9) and lack of effect on K^+ contractions (Figure 10). These data are consistent with the reported inhibition by YM of rat aortas contractions by other GPCRs which are known to involve G_q (Table 3; Chapter 1.2.4). We also found that the concentration of YM used in the ex vivo studies was effective for inhibition of tcLIGRLO activation of PAR2-Ca^{2+} signal in HEK293 (Figure 13B and C). These data demonstrate that tcLIGRLO-induced contractions are mediated by a G_q pathway, providing evidence of an unidentified GPCR as the target of tcLIGRLO in mouse femoral arteries.

2.4.3 YM inhibition of PAR2 Ca^{2+} signalling pathway

We found that YM’s use displayed an all-or-none inhibitory response, resulting in a steep Hill coefficient (>1) estimated in the Ca^{2+} signal assay to tcLIGRLO in PAR2WT cells following YM pre-treatment (2.6±1.0; Figure 15). We found a 5 min incubation threshold for inhibition of PAR2 Ca^{2+} signal by YM (1µM) and complete inhibition after 10 min. A small reduction in effectiveness of YM (1µM) after 30 min incubation, potentially due to decreased peptide stability, was observed in a single replicate. This decreased peptide stability of YM after a prolonged period has not been reported by previous studies. To
date, there are few studies that investigate the effects of YM inhibition on PARs signalling, and in particular, PAR2 signalling. In the study by Thibeault & Ramachandran (2020), where they measured β-arrestin recruitment in HEK293 cells following the addition of SLIGRL, 100nM of YM resulted in reduced EC$_{50}$ values in β-arrestin-1 and -2 recruitment in comparison to untreated cells by nearly 1.5 – 2 folds. We are not aware of any studies that have reported a pIC$_{50}$ value for the effects of YM on PAR2-Ca$^{2+}$ signalling stimulated by tcLIGRLO in HEK293 cells.
Chapter 3

3 Assessing for GPCR activation with the TANGO assay

3.1 Introduction

Of the 800 human GPCRs, over 150 of these receptors are classified as orphan receptors (i.e., GPCRs whose endogenous and synthetic ligands remain undetermined) (Pierce et al., 2002; Stockert & Devi, 2015). A limit to traditional high throughput screening methods for potential orphan receptor hits with GPCR ligands is they rely on assays of second messengers (e.g., Ca\(^{2+}\), cAMP) mediated by the different G\(\alpha\) proteins—G\(s\), G\(i\), G\(_{12/13}\), or G\(_q\). (Chapter 1.3.2). The rate of de-orphanization has decreased from its peak during the 1990s – early 2000s, at around 10 de-orphanized GPCRs per year (Hauser et al., 2017, 2020). While GPCRs interact with the heterotrimeric G-protein complex formed by G\(\alpha\) and G\(\beta/\gamma\), this does not preclude GPCR signalling via G-protein independent pathways (Heuss et al., 1999; Tang et al., 2012). For example, \(\beta\)-arrestin recruitment assays provide another avenue for measuring GPCR activation independent of G-protein signalling. The TANGO assay applies the knowledge that most GPCRs interact with \(\beta\)-arrestin-1 and/or -2 (Chapter 1.3.2.2). Specifically, the TANGO assay uses GPCR constructs containing modified C-terminus fused with a transcriptional activator that is separated by a cleavage site, where \(\beta\)-arrestin-2 binds to following external ligand binding to the receptor (Figure 2; Chapter 1.3.2.2). Following receptor activation from ligand binding, this allows the transcriptional activator to enter the nucleus to upregulate the luciferase reporter gene, which gives off a luminescence signal (Figure 2; Chapter 1.3.2.2). Several GPCRs have been deorphanized using the TANGO assay since the time of its introduction almost 20 years ago (Barnea et al., 2008; Kroeze et al., 2015; Meder et al., 2003; Wittamer et al., 2003). The advantage of this approach is that the ligand screening is independent of the G\(\alpha\) subtype protein that is coupled to the native receptor and is independent of specific second messenger signalling.
In chapter 2, we showed that tcLIGRLO activates $G_\text{q}$-dependent contractions of mouse femoral arteries. The GPCR linking tcLIGRLO to contraction is undetermined in PAR2KO femoral arteries. In this study, we proposed to use the TANGO assay to identify potential human orphan GPCRs as targets. tcLIGRLO is a known PAR2 activator, but has not been tested in the TANGO system. First, we compared tcLIGRLO to other known PAR2APs in PAR2 expressing cells using the TANGO assay. Next, we used tcLIGRLO in cells expressing CCRL2, GPR15, SUCNR1, and GPR135 using the TANGO assay. These candidate receptors were selected based on a pilot study (unpublished data, Dr. McGuire) screen of $>$70 orphan GPCRs using the human orphan GPCR PathHunter® assay contract service screen. Expression of the mouse orthologues for these receptors have been confirmed in mouse blood vessels, including the mouse femoral artery of PAR2KO (unpublished data, Dr. McGuire). By the time of this study, the orphan receptor GPR91 was de-orphanized and renamed as SUCNR1, with succinate as its only confirmed endogenous ligand to date (He et al., 2004). GPR15 and CCRL2 have their prospective ligands GPR15L/thrombomodulin and chemokines/chemerin, respectively (Biber et al., 2003; Hartmann et al., 2008; Pan et al., 2017; Suply et al., 2017), whereas ligands for GPR135 remain undetermined (Watkins & Orlandi, 2020). In this chapter, our goal was to validate the TANGO assay for PAR2 activation by tcLIGRLO, in concurrence to the assessment for GPCR activation with the four receptors. Here, we confirmed tcLIGRLO activated PAR2, but had less activity compared with the PAR2APs SLIGRL and 2fLIGRLO.

### 3.2 Materials and Methods

#### 3.2.1 Chemical reagents and drug solutions

Chemical reagents and buffer solutions were purchased from Thermo Fisher Scientific (Mississauga, ON). PAR2APs SLIGRL, tcLIGRLO, and 2fLIGRLO were synthesized as amides (GenScript). Stock solution of SLIGRL, tcLIGRLO, and 2fLIGRLO were made in 25mM HEPES buffer, pH 7.4. Dilutions of synthetic peptides were made at room temperature in 1x Hank’s Balanced Salt Solution (HBSS) containing $\text{Ca}^{2+}$ (1.3mM),
magnesium (0.9mM), and glucose (5.6mM). D-luciferin, sodium salt for Glo reagent was purchased from GoldBio (St. Louis, MO), and 15mg/mL stock solution was made in double-distilled H2O according to manufacturer’s protocol.

3.2.2 Cloning and transfection
The plasmid constructs of CCRL2, GPR15, GPR135, SUCNR1, and PAR2 were purchased from Addgene, which distributes these constructs designed by the Roth lab as part of the PRESTO-TANGO kit. Plasmid DNA purification was performed with HiSpeed Plasmid Midi Kit from Qiagen (Germantown, MD). Cell culture reagents were purchased from Thermo Fisher Scientific. HTLA cells (a HEK293 cell line stably expressing a tetracycline transactivator-dependent luciferase, reporter, and β-arrestin-2-Tobacco Etch Virus fusion gene) were provided to Dr. Rithwik Ramachandran by the Barnea lab (Brown University, Providence, RI) and maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 1% sodium pyruvate, penicillin streptomycin solution (50 000 units penicillin, 50 000µg streptomycin), 200µg/mL hydromycin B, 500µg/mL G418, and 5µg/mL puromycin at 37°C, 5%CO2. X-tremeGene 9 DNA Transfection Reagent Transfection was purchased from Roche (Basel, Switzerland) and was diluted with Opti-MEM Reduced Serum Medium, without Phenol Red containing L-glutamine and HEPES (Thermo Fisher Scientific) to a concentration of 3µL reagent/ 100µL medium. On day 1, at 70-80% confluency, cells were sub-cultured with 0.25% trypsin-EDTA (1X) and seeded on a 9.5cm² 6-well plate at a density of 0.7 x 10⁶ cells/mL. Approximately 1µg of DNA was incubated in 100µL of diluted X-tremeGENE 9 DNA Transfection Reagent for 20 min. In a dropwise manner, the transfection complex was added to cells, which were then incubated for 24h at 37°C, 5% CO2.

3.2.3 Luciferase reporter assay
On day 2, cell media was switched with serum-free media to stop cells from dividing. Cells were then re-plated on a 96-well polystyrene microplate and left alone for at least 20 min at 37°C, 5% CO2 prior to drug treatment. Diluted drug solutions containing
tcLIGRLO, SLIGRL, and 2fLIGRLO were added to wells according to a 1:1 (volume) ratio of drug to cell solution. HBSS without drug was used as control treatment. Cells were incubated with PAR2AP or control for 24h. The concentrations of PAR2APs were chosen according to published studies (Table 1; Chapter 1.1) with these PAR2APs in HEK293 (SLIGRL, 0.3 – 300µM; 2fLIGRLO and tcLIGRLO, 0.1 – 100µM). Experiments were conducted to determine that a 24h-incubation time was sufficient to detect a drug response for PAR2. On day 3, the drug-cell media mixture was aspirated from wells and replaced with 20µL Glo reagent containing 108mM Tris-HCl, 42mM Tris-Base, 75mM NaCl, 3mM MgCl₂, 5mM dithiothreitol, 0.14 mg/mL D-luciferin, 1.1mM ATP, and 0.25% v/v Triton X-100 as described (Laroche & Giguère, 2019). After incubating cells with Glo reagent for 30 min at room temperature in the dark, the luciferase-generated luminescence was recorded using the Mithras LB 940 Multimode Microplate Reader (Berthold Technologies GmbH and Co. KG; Bad Wildbad, DE). Plates were read at room temperature (20°C). The dwell time on each well was 20s. Each 96-well plate contained 12 columns x 8 rows of wells. Columns contained replicate doses for drugs (up to three) and rows contained different concentrations of drug or vehicle. The sequence of measurements started with the first row and first column, then continued to the next row. The first sample read was the well containing cells treated with the highest concentration of each drug. The last sample in each row contained the control (0 drug; HBSS Ca²⁺) treated cells

3.2.4 Data and statistical analyses

Luciferase luminescence data are reported in Figures as the average luminescence of drug-treated cells relative to baseline. For each replicate sample, this calculation is: luminescence value in well divided by baseline value. The baseline for each replicate is the luminescence of cells treated with HBSS containing Ca²⁺ from the same sample as the column. Data are reported as mean ± S.E. (error bars) for n=number of independent experiments with triplicate samples in each experiment. E_max values were compared by Kriskal-Wallis test followed by Dunn’s post hoc. Nonlinear regression curve fits were
determined using the mean data from each group. Curves were compared between groups using F-test. *p<0.05 were considered significant.

3.3 Results

3.3.1 PAR2 activation with tcLIGRLO, SLIGRL, 2fLIGRLO

We detected PAR2 activation by tcLIGRLO in the TANGO assay (Figure 16). In a pilot experiment (n=1), the average response of cells to 300µM SLIGRL at 12h (ratio of signal to baseline: 5±1 for 3 replicates, mean±SD) was similar to effects shown at 24h (Figure 16; 3.1±0.6 for n=3 with 3 replicates, mean±SEM). In the 24h-treatment of cells with PAR2APs SLIGRL (n=3), 2fLIGRLO (n=3), and tcLIGRLO (n=7) in the TANGO assay, $E_{\text{max}}$ values did not differ between PAR2APs (Figure 16, Table 10). The rank order of potency according to EC$_{50}$ values was: 2fLIGRLO > tcLIGRLO > SLIGRL.
Figure 16. PAR2 activation with SLIGRL, 2fLIGRLO, and tcLIGRLO in PAR2-transfected HTLA cells using the TANGO assay.

Luminescence values to 24h-treatment with drugs were normalized against baseline luminescence values (i.e., cells treated with 1x HBSS) to get fold increase over baseline values. Nonlinear regression curve fit is shown as mean ± S.E. (error bars). $E_{\text{max}}$ and $pEC_{50}$ are provided in Table 10. $E_{\text{max}}$ values did not significantly differ between the three peptides ($p>0.05$; Kriskal-Wallis). The peptide 2fLIGRLO demonstrated the highest potency, followed by a significant rightward shift by tcLIGRLO and SLIGRL (*$p<0.05$; F-test). Numbers within parentheses beside peptide indicate number of independent experiments that were done with respective peptide.
Table 10. $E_{\text{max}}$ and $p\text{EC}_{50}$ values of PAR2 activation with PAR2APs in PAR2-transfected HTLA cells in the TANGO assay

<table>
<thead>
<tr>
<th></th>
<th>SLIGRL$^a$</th>
<th>2fLIGRLO$^a$</th>
<th>tcLIGRLO$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$E_{\text{max}}$ (%)</td>
<td>3.13±0.46</td>
<td>4.55±2.43</td>
<td>2.13±0.94</td>
</tr>
<tr>
<td>$p\text{EC}_{50}$ (M)</td>
<td>3.92±0.08*</td>
<td>5.27±0.14*</td>
<td>5.06±0.14</td>
</tr>
</tbody>
</table>

CRCs were performed with 0.3 – 300µM SLIGRL and 0.1 – 100µM 2fLIGRLO and tcLIGRLO. n=number of independent experiments with 3 replicates each; *p<0.05 compared to tcLIGRLO, F-test.

a, n=3; b, n=7; c, mean±SEM; d, $E_{\text{max}}$ is maximum agonist signal relative to baseline signal (1x HBSS)
3.3.2 Effects of tcLIGRLO on CCRL2, GPR15, GPR135, and SUCNR1 expressing HTLA cells in TANGO assay

Treatment of GPR135 expressing HTLA cells with 0.3 µM tcLIGRLO generated a two-fold increase in luminescence relative to baseline (Figure 17; *p<0.05, 0.3µM tcLIGRLO for GPR135 vs. PAR2). This same treatment did not result in a detectable luminescence signal in PAR2 expressing HTLA cells. (Figure 17). We did not detect activation of CCRL2, GPR15, and SUCNR1 by tcLIGRLO under the conditions of the TANGO assay (p>0.05).
Figure 17. TANGO luminescence of tcLIGRLO treated HTLA cells-expressing PAR2, SUCNR1, GPR135, GPR15, or CCRL2.

HTLA cells expressing specific GPCR constructs as listed above, were incubated for 24h with 1x HBSS, or different doses of tcLIGRLO. Bars show the luminescence signal generated in presence of substrate (n.b. added after 24 h) relative to baseline (HBSS) as described in Methods. *p<0.05; 0.3µM tcLIGRLO, PAR2 vs. GPR135 by one-way ANOVA and Bonferroni post hoc. Data are shown as mean ± S.E. (error bars). Numbers within parentheses beside receptor indicate number of independent experiments that were conducted with respective receptor.
3.4 Discussion

The main finding of this study is that we detected activation of PAR2 and human GPR135 by tcLIGRLO using the TANGO assay. The results from this study will be used to explore the mechanism of vascular smooth muscle contraction by tcLIGRLO.

3.4.1 PAR2 activation with SLIGRL, 2fLIGRLO, and tcLIGRLO with the TANGO assay

Similar to the study by Thibeault & Ramachandran (2020), who found different mechanisms regulating β-arrestin interaction with PAR2 following tethered ligand (by protease) and synthetic ligand peptide-mediated activation, there may be differences in β-arrestin recruitment between the three PAR2APs. This would account for the differences exhibited by the three PAR2APs in the TANGO assay. In comparison to tcLIGRLO and SLIGRL, 2fLIGRLO is the most potent agonist out of the three peptides, with an EC_{50} value that is approximately 8 folds higher in magnitude than SLIGRL and tcLIGRLO (Table 10 and Table 1 from Chapter 1.1). We found that there was reduced luminescence signalling at 100µM tcLIGRLO, possibly due to desensitization effects (Figure 10). Hence, we showed the curve fit for tcLIGRLO as constrained within the concentration range 0.1 – 30µM. Since the TANGO assay was effective for detecting PAR2 activation with ligands, testing non-peptide PAR2 ligands that have become available would be useful to exploring the structure activity relationships of PAR2 ligands in the TANGO assay.

3.4.2 β-arrestin activity with CCRL2, GPR135, GPR15, and SUCNR1

At 0.3 µM tcLIGRLO, a concentration that did not activate PAR2, we detected a 2-fold increase in luminescence signal with GPR135 cells (Figure 17). We interpret this result as evidence of GPR135 as a target of tcLIGRLO. We speculate that GPR135 is the target of tcLIGRLO in vascular smooth muscle of mouse femoral arteries. In chapter 4, we expand upon these discussion points.
Chapter 4

4 Overall discussion and conclusions

4.1 Overall discussion

4.1.1 tcLIGRLO-smooth muscle contractions

YM inhibition of tcLIGRLO-induced contractions indicates a novel $G_q$-signalling in vascular smooth muscle of mouse femoral arteries. Discovering this novel receptor that mediates smooth muscle contractions provides another avenue for investigating smooth muscle function during the ageing process. To supplement our findings, it is suggested to look at the expression profiles of proteins mentioned in Chapter 2.4.1 following tcLIGRLO-treatment in vascular smooth muscle from aged and young mice. For instance, since there was a decreased expression of smooth muscle contraction proteins vinculin and phospho-focal-adhesion kinase 397 in aged versus young vessels from rats (Chapter 2.4.1), we can see if this interaction is present in response to tcLIGRLO in vascular smooth muscle cells from aged and young mice.

While we did not find any sex differences, establishing age as a factor that contributes to differences in tcLIGRLO-induced contractions prompts for further investigation of potential sex differences in young versus older mice. Additionally, the expression profile of this tcLIGRLO-activated receptor is not known in other tissues such as gastrointestinal- or cardiac smooth muscle. Potential expression of this tcLIGRLO-activated receptor in other tissues would imply novel roles for this receptor such as a regulator of gastric motility in the gastrointestinal tract or of ventricular contractions in the heart.

4.1.2 In vivo studies with tcLIGRLO and YM

A potential extension of this current work is to pursue in vivo studies, which could include dosing mice with tcLIGRLO and YM while measuring their effects on variables such as blood pressure and heart rate. Such in vivo studies would be useful to determining
the potential for tcLIGRLO and YM as potential therapeutic agents for blood vessel function. Indeed, previous studies have looked at the effects of YM \textit{in vivo}, where they administered YM as an antithrombotic agent in rats, mice, and cynomolgus monkeys (Kawasaki et al., 2003, 2005; Uemura, Kawasaki, et al., 2006; Uemura, Takamatsu, et al., 2006b). It is important to note that while YM dose-dependently inhibited thrombus formation in all studies, there was an adverse effect of prolonged bleeding. This issue of prolonged bleeding is something to monitor in future \textit{in vivo} studies involving tcLIGRLO and YM. In terms of YM, our study was one of the first studies to test the effects of YM inhibition on PAR2-Ca$^{2+}$ signalling stimulated by tcLIGRLO. Previous studies, which we summarized in Chapter 1.2.3, thus far have used YM to further delineate the signalling networks of PAR2.

4.1.3 tcLIGRLO as a potential ligand for GPR135

In a ligand-independent fashion, GPR135 forms a heterodimer with melatonin receptor 2 as a method of activation (Chapter 1.3.3.2). Melatonin signalling via receptors such as melatonin receptor 2 elicits vasoconstriction in pig coronary arteries, whereas it induces vasorelaxation in pig pulmonary arteries \textit{ex vivo} (Weekley, 1993). Melatonin does not bind to GPR135 (Oishi et al., 2017), but its function in heterodimerizing with melatonin receptor 2 presents a potential role for GPR135 in regulating vascular tone. Currently, the only known physiological role of GPR135 is it is a prominent hypermethylation site in lung and ovarian cancers (Chapter 1.3.3.2). Potentially, the absence of GPR135 activation via hypermethylation leads to aberrant melatonin signalling in certain cancers. Considering how GPR135’s only known method of activation is forming a heterodimer with melatonin receptor 2, identifying a new ligand for GPR135 would be a useful tool in delineating GPR135’s role in cancer.

Based on results of screening with the TANGO assay, tcLIGRLO was a ligand for GPR135. We speculate that GPR135 is a potential target for tcLIGRLO at lower concentrations. tcLIGRLO would not be unique among ligands that activate GPCR families. Fluoxetine binds to additional receptors (e.g., SSTR3 somatostatin receptor and
σ₁-receptor) in addition to its primary target (i.e., the serotonin receptors) (Keiser et al., 2009; Kroeze et al., 2015). We also detected luminescence signal, indicating GPCR activation by ligands using SLIGRL and 2fLIGRLO at various incubation times in PAR2-transfected HTLA cells. Similar to Kroeze et al. (2015), we found that the length of exposure to agonists in the TANGO luminescence assay affected the signalling response. Our pilot study (n=1) for SLIGRL indicated that the 12h-treatment was similar in effects to the 24h-treatment. Exposing our cells to 24h with SLIGRL and 2fLIGRLO ensured detectable signal when running assays with the two PAR2APs at the same time. Luminescence signals to these two PAR2APs were used as positive controls to compare our TANGO signal to tcLIGRLO.

### 4.1.4 Future directions

To further validate our findings from the TANGO assay, we recommend testing for GPR135 activation with tcLIGRLO via another method such as the bioluminescence resonance energy transfer (BRET) assay. In the BRET assay, upon β-arrestin recruitment, the donor probe attached to β-arrestin transfers energy to the acceptor probe that is fused with the receptor (Rajagopal et al., 2010; Ramachandran et al., 2009). This energy transfer results in luminescence signalling, which signifies GPCR activation (Rajagopal et al., 2010; Ramachandran et al., 2009). The difference between the TANGO and BRET assay is the TANGO assay relies on the reporter-gene expression of luciferase following the release of the transcriptional activator from the receptor, while BRET experiments rely on the receptor to β-arrestin interaction in real-time for a signal response (Rajagopal et al., 2010; Ramachandran et al., 2009). Additionally, the TANGO assay involves testing activation of non-native receptors, while BRET experiments allow for the measurement of β-arrestin recruitment to receptors in their natural cell systems. Expression of receptors in their unnatural cell environment may change properties in their downstream signalling pathways.

Another follow-up study is to investigate the potential effects of GPR135 activation on Gq/Ca²⁺ signalling. We suggest assessing for Ca²⁺ signals following tcLIGRLO-treatment.
in both mouse vascular smooth muscle cells (GPR135WTs) and GPR135KOs. Absence of Ca\(^{2+}\) signalling in GPR135KO cells would provide more evidence for GPR135 as a candidate for the tcLIGRLO-activated receptor.

### 4.2 Conclusions

In conclusion, mouse femoral contractions elicited by tcLIGRLO did not differ by sex and present age-related effects. The downstream pathways mediating these tcLIGRLO-induced contractions involve G\(_q\) signalling. tcLIGRLO activated human PAR2 and human GPR135 in the TANGO assay. Further study of this novel G\(_q\) signalling mechanism and the identification of the tcLIGRLO-activated receptor will provide novel insight on human health and diseases in the field of vascular biology.
References


Storch, U., Blodow, S., Gudermann, T., & Mederos y Schnitzler, M. (2015). Cysteinyl Leukotriene 1 Receptors as Novel Mechansensors Mediating Myogenic Tone Together With Angiotensin II Type 1 Receptors—Brief Report. Arteriosclerosis,


Appendices

Appendix 1: Animal use protocol

<table>
<thead>
<tr>
<th>PI</th>
<th>McGuire, John</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol #</td>
<td>2018-109</td>
</tr>
<tr>
<td>Status</td>
<td>Approved (w/o Stipulation)</td>
</tr>
<tr>
<td>Approved</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Expires</td>
<td>10/01/2022</td>
</tr>
<tr>
<td>Title</td>
<td>Novel receptor in blood vessels of mice</td>
</tr>
</tbody>
</table>
Curriculum Vitae

Name: Joselia Carlos

Education
MSc in Medical Biophysics  
University of Western Ontario  
London, Ontario, Canada  
2019 – present

BMSc in Medical Cell Biology  
University of Western Ontario  
London, Ontario, Canada  
2014 – 2019

Honours and Awards
Western Graduate Research Scholarship ($4500/year)  
2019 – 2020, 2020 – 2021

Western Scholarship of Excellence ($2000)  
2014

Research Experience
Graduate Student Research Assistant  
University of Western Ontario, London, ON  
Dr. John McGuire, Medical Biophysics  
2019 – present

Undergraduate Student Researcher  
London Regional Cancer Program, Victoria Hospital, London, ON  
Dr. Alison Allan, Anatomy and Cell Biology, Oncology  
2018 – 2019

Undergraduate Student Researcher  
London Regional Cancer Program, Victoria Hospital, London, ON  
Dr. Eva Turley, Anatomy and Cell Biology, Oncology  
2016 – 2018

Teaching Experience
Graduate Teaching Assistant  
MEDBIO 4700B  
University of Western Ontario, London, ON  
Jan 2020 – April 2021
Graduate Teaching Assistant
MEDBIO 3501A
University of Western Ontario, London, ON
Sept 2020 – Dec 2020

**Extracurricular Activities**
Executive Committee Member
Science-to-Business Network, London Chapter, ON
Nov 2019 – Aug 2021

**Professional Society Memberships**
British Journal Pharmacology Society (2020 – 2021)

**PUBLICATION HISTORY**

**Peer-Reviewed Manuscripts**

**Published Abstracts:**


